

## **INDEPENDENT AUDITORS' REPORT**

### **TO THE MEMBERS OF ZYDUS PHARMACEUTICALS LIMITED**

#### **Report on the Audit of the Financial Statements**

##### **Opinion**

We have audited the accompanying financial statements of Zydus Pharmaceuticals Limited ('the Company'), which comprise the Balance Sheet as at 31<sup>st</sup> March 2025, the Statement of Profit and Loss (including other comprehensive income), the Statement of changes in Equity and the Statement of cash flows for the year then ended, and notes to the financial statements, including a summary of material accounting policies and other explanatory information ("the Financial Statements").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Companies Act, 2013 ('the Act') in the manner so required and give a true and fair view in conformity with the Indian Accounting Standards prescribed under section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015, as amended, ('Ind AS') and other accounting principles generally accepted in India, of the state of affairs of the Company as at 31<sup>st</sup> March, 2025, and its loss, total comprehensive income, the changes in equity and cash flows for the year ended on that date.

##### **Basis for Opinion**

We conducted our audit of the financial statements in accordance with the Standards on Auditing ('SAs') specified under section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the financial statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ('ICAI') together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules made thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on the financial statements.

##### **Information other than the Financial Statements and Auditor's Report thereon**

The Company's Board of Directors is responsible for the other information. The other information comprises the information included in the Board's Report, but does not include the financial statements and our audit reports thereon.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

##### **Management's Responsibility for the financial statements**

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Act with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance including other comprehensive income, cash flows and changes in equity of the Company in accordance with the Ind-AS and other accounting principles generally accepted in India. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate implementation and maintenance of accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of

the accounting records, relevant to the preparation and presentation of the financial statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those Board of Directors is also responsible for overseeing the Company's financial reporting process.

#### **Auditor's Responsibilities for the Audit of the financial statements**

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- a) Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- b) Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- c) Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- d) Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- e) Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the Financial Statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Financial Statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Financial Statements

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

## Report on Other Legal and Regulatory Requirements

As required by the Companies (Auditor's Report) Order, 2020 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Act, we give in the "Annexure A" a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.

As required by Section 143(3) of the Act, we report that:

- a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
- b) In our opinion, proper books of account as required by law have been kept, so far as it appears from our examination of those books. The backup of the books of accounts and other books and papers maintained in electronic mode, has been maintained on a daily basis on servers physically located in India during the year.
- c) The Balance Sheet, the Statement of Profit and Loss including Other Comprehensive Income, the Cash Flow Statement and Statement of Changes in Equity dealt with by this report are in agreement with the books of account.
- d) In our opinion, the aforesaid financial statements comply with the Ind AS specified under Section 133 of the Act.
- e) On the basis of the written representations received from the directors as on March 31, 2025 taken on record by the Board of Directors, none of the directors, is disqualified as on March 31, 2025 from being appointed as a director in terms of section 164(2) of the Act
- f) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure B" attached to this report. Our report expresses an unmodified opinion on the adequacy and operating effectiveness of the Company's internal financial controls over financial reporting.
- g) With respect to the other matters to be included in the Auditor's Report in accordance with the requirements of section 197(16) of the Act, as amended, in our opinion and to the best of our information and according to the explanations given to us, no remuneration paid by the company to its directors during the year.
- h) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
  - i. The Company does not have any pending litigations which would impact its financial position
  - ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses;
  - iii. There has been no delay in transferring amounts, required to be transferred, to the Investor Education and Protection Fund by the Company.
  - iv.
    - (a) The management has represented that, to the best of its knowledge and belief, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the company to or in any other persons or entities, including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend to or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;
    - (b) The management has represented that, to the best of its knowledge and belief, no funds have been received by the company from any persons or entities, including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by

or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries; and

- (c) Based on such audit procedures that we have considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations given under (a) and (b) above, contain any material misstatement.
- v. During the year, the company has not declared any dividends. Hence, reporting of compliance under section 123 of the Companies Act, 2013 is not applicable.
- i) Based on our examination, which included test checks, the Company has used accounting software for maintaining its books of account for the financial year ended 31 March 2025 which has a feature of recording audit trail (edit log) facility and the same has been operational throughout the year for all relevant transactions recorded in the accounting software. Further, during our audit, we did not come across any instance of audit trail feature being tampered with and the audit trail has been preserved by the company as per the statutory requirements for record retention.

Place: Ahmedabad  
Date: 12<sup>th</sup> May, 2025  
UDIN: 25129675BMOJHV2605

For **MUKESH M. SHAH & CO.,**  
Chartered Accountants  
Firm Registration No.: 106625W

sd/-  
**Karnik K. Shah**  
Partner  
Membership No.: 129675

## **“Annexure A” to the Independent Auditors’ Report**

**The Annexure referred to in Independent Auditors’ Report to the members of the Company on the financial statements for the year ended March 31, 2025.**

Based on the audit procedures performed for the purpose of reporting a true and fair view on the financial statements of the Company and taking into consideration the information and explanations given to us and the books of account and other records examined by us in the normal course of audit, we report that:

- (i) (a) A. The Company has maintained proper records showing full particulars, including quantitative details and situation of Property, plant and equipment and Capital work-in-progress and relevant details of right-of-use-assets.  
  
B. The Company has maintained proper records showing full particulars of intangible assets.
- (b) Some of the Property, plant and equipment, capital work in progress and right of use assets were physically verified during the year by the management in accordance with a program of verification, which in our opinion provides for physical verification of all the Property, Plant and Equipment, capital work in progress and right of use assets at reasonable intervals having regard to the size of the company and the nature of its activities. According to the information and explanations given to us, no material discrepancies were noticed on such verification.
- (c) According to the information and explanations given to us and based on the examination of the books of account and the lease agreements provided to us, we report that, the lease agreements, comprising all the immovable properties of land and buildings which are leasehold, are held in the name of the Company as at the balance sheet date.
- (d) The Company has not revalued any of its property, plant and equipment (including Right of Use assets) and intangible assets during the year.
- (e) According to the information and explanations given to us and the records examined by us and based on the examination, no proceedings have been initiated during the year or are pending against the Company as at 31<sup>st</sup> March, 2025 for holding any benami property under the Benami Transactions (Prohibition) Act, 1988 (as amended in 2016) and rules made thereunder.
- (ii) (a) The inventories were physically verified by the Management at reasonable intervals during the year. In our opinion and based on information and explanations given to us, the coverage and procedure of such verification by the Management is appropriate having regard to the size of the Company and the nature of its operations. No discrepancies of 10% or more in the aggregate for each class of inventories were noticed on such physical verification of inventories when compared with the books of account.
- (b) According to the information and explanations given to us, the company has not been sanctioned any working capital facility on the basis of security of current assets from banks and financial institutions at any point of time during the year and hence reporting under clause (ii)(b) of the order is not applicable.
- (iii) According to the information and explanations given to us, the company has not made investments in, provided any guarantee or security or granted any loans or advances in the nature of loans, secured or unsecured, to companies, firms, Limited Liability Partnerships or other parties during the year. Accordingly, other clauses of the paragraph of the Order are not applicable to the company for the current year.
- (iv) According to the information and explanations given to us and on the basis of our examination of the records, the Company has not given any loans, guarantee and security or made any investments to which provisions of section 185 and 186 of the Act is applicable, and accordingly reporting under clause (iv) of the Order is not applicable to the Company.

- (v) The Company has not accepted any deposits within the meaning of the provisions of section 73 to 76 or any other relevant provisions of the Act and the rules framed thereunder. Further, according to the information and explanations given to us, no order has been passed by the Company Law Board of National Company Law Tribunal or Reserve Bank of India or any court or any other Tribunal, in this regard.
- (vi) As per the information and explanations provided to us, the company is not required to maintain the cost records pursuant to the Companies (Cost Records and Audit) Rules, 2014, as amended prescribed by the Central Government under sub-section (1) of section 148 of the Act, hence, reporting under this clause is not applicable to the company.
- (vii) According to the information and explanations given to us, in respect of statutory dues:
  - (a) The company has been generally regular in depositing undisputed statutory dues including Goods and Services tax, Provident Fund, Employees' State Insurance, Income-tax, Sales-tax, Service tax, Duty of Custom, Duty of Excise, Value added Tax, Cess and any other material statutory dues applicable to it with the appropriate authorities.
  - (b) There was no undisputed amount payable in respect of Goods and Service Tax, Provident Fund, Employees' State Insurance, Income-tax, Sales-tax, Service tax, Duty of Custom, Duty of Excise, Value added Tax, Cess and any other material statutory dues in arrears as at March 31, 2025 for a period of more than six months from the date they became payable.
  - (c) There are no dues under dispute for the Income Tax, Sales Tax, Service tax, Goods and Service Tax, Customs duty, Excise Duty, and Value added tax and other material statutory dues as on 31<sup>st</sup> March, 2025.
- (viii) According to the information and explanations given to us, there were no transactions relating to previously unrecorded income that were surrendered or disclosed as income in the tax assessments under the Income Tax Act, 1961 (43 of 1961) during the year.
- (ix) According to the information and explanations given to us and on the basis of our examination of the books of account, we report that -
  - (a) The company has not taken any loans during the year and there is no outstanding loan at the end of the year; hence, reporting under this clause of the order is not applicable.
  - (b) The Company has not been declared wilful defaulter by any bank or financial institution or other lender.
  - (c) the company has not taken any term loans during the year, hence, reporting under this clause of the order is not applicable;
  - (d) we report that the funds raised on short term basis have not been utilized for the long-term purpose.
  - (e) the company has not taken any funds from any entity or person on account of or to meet the obligations of its Subsidiaries, associates or joint ventures.
  - (f) we report that the Company has not raised any loans during the year on the pledge of securities held in its subsidiaries, joint ventures or associate company.
- (x) (a) The Company did not raise any money by way of initial public offer or further public offer (including debt instruments) during the year and hence reporting under this clause of the Order is not applicable to the Company.
 

(b) The Company has made preferential allotment of optionally convertible non-cumulative redeemable preference shares ("OCRPS") during the year and has complied with the requirements of applicable provisions of section 42 & section 62 of the companies Act 2013. Further, the funds raised by issuance of such OCRPS have been used by the company for the purposes for which the funds were raised.

- (xi) (a) To the best of our knowledge and according to the information and explanations given to us, no fraud by the Company or on the Company has been noticed or reported during the year.
- (b) According to the information and explanations given to us, no report under sub-section (12) of section 143 of the Companies Act has been filed by the auditors in Form ADT-4 as prescribed under rule 13 of Companies (Audit and Auditors) Rules, 2014 with the Central Government, during the year.
- (c) According to the information and explanations given to us, there is no whistle blower complaints received by the Company during the year.
- (xii) The Company is not a Nidhi company. Accordingly, reporting under clause (xii) of the Order is not applicable to the Company.
- (xiii) In our opinion and according to the information and explanations given to us and based on our examination of the records of the Company, transactions with the related parties are in compliance with section 177 and 188 of the Act, where applicable, and details of such transactions have been disclosed in the financial statements as required by the applicable accounting standards.
- (xiv) (a) In our opinion and based on our examination, the Company has an adequate internal audit system commensurate with the size and the nature of its business.
- (b) We have considered the reports of the internal auditors for the period under audit.
- (xv) According to the information and explanations given to us and based on our examination of the records of the Company, the Company has not entered into non-cash transactions with directors or persons connected with them and, hence, provisions of section 192 of the Act is not applicable to the company. Accordingly, reporting under clause (xv) of the Order is not applicable to the Company.
- (xvi) According to the information and explanations given to us and based on our examination of the records of the Company, we report that
  - (a) The Company is not required to be registered under section 45-IA of the Reserve Bank of India Act 1934;
  - (b) The Company has not conducted any non-banking or housing finance activities during the year;
  - (c) The Company is not a Core Investment Company, as defined in the regulations made by the Reserve Bank of India;
  - (d) The Group has more than One Core Investment Company (two Core Investment Companies) as part of the Group.
- (xvii) The company has not incurred cash losses during the current year. There was cash loss of Rs. 1,569 Lacs during the preceding year.
- (xviii) There has been no resignation of the statutory auditors of the Company during the year.
- (xix) On the basis of the financial ratios, ageing and expected dates of realization of financial assets and payment of financial liabilities, other information accompanying the financial statements and our knowledge of the Board of Directors and Management plans and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report indicating that Company is not capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date. We, however, state that this is not an assurance as to the future viability of the Company. We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the Company as and when they fall due.
- (xx) On the basis of information and explanations given to us and based on the examination of the records of the company, the provisions of Corporate Social Responsibility ("CSR") of the Act is not applicable to the company. Accordingly, reporting under clause 3(XX) of the Order is not applicable for the year.

For **MUKESH M. SHAH & CO.,**  
Chartered Accountants  
Firm Registration No.: 106625W

Place: Ahmedabad  
Date: 12<sup>th</sup> May, 2025  
UDIN: 25129675BMOJHV2605

sd/-  
**Karnik K. Shah**  
Partner  
Membership No.: 129675

## **“ANNEXURE B” TO THE AUDITORS’ REPORT**

### **Report on the Internal Financial Control clause (i) of sub-section 3 of section 143 of the Companies Act, 2013 (“the Act”)**

We have audited the internal financial controls over financial reporting of Zydus Pharmaceuticals Limited (“the company”) as of March 31, 2025 in conjunction with our audit of the financial statements of the Company for the year ended on that date.

#### **Management Responsibility for Internal Financial Controls**

The company’s management is responsible for establishing and maintaining internal financial control based on the internal control over financial reporting criteria established by the company considering the essential components of internal control stated in the Guidance Note on audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India [“ICAI”]. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company’s policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Act.

#### **Auditors’ Responsibility**

Our responsibility is to express an opinion on the company’s internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the “Guidance Note”) and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Act, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Controls and, both issued by the ICAI. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial control system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor’s Judgement, including the assessment of the material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company’s internal financial controls system over financial reporting.

#### **Meaning of Internal Financial Controls Over Financial Reporting**

A company’s internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal financial control over financial reporting includes those policies and procedures that:

1. pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company;
2. provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and

3. provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

#### **Inherent limitations of Internal Financial Controls Over Financial Reporting**

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

#### **Opinion**

In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2025, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

For **MUKESH M. SHAH & CO.,**  
Chartered Accountants  
Firm Registration No.: 106625W

sd/-  
**Karnik K. Shah**  
Partner  
Membership No.: 129675

Place: Ahmedabad  
Date: 12<sup>th</sup> May, 2025  
UDIN: 25129675BMOJHV2605

**ZYDUS PHARMACEUTICALS LIMITED [CIN : U24290GJ2019PLC111689]**

**Balance Sheet as at March 31, 2025**

Particulars	Note No.	INR-Lakh	
		As at March 31	
		2025	2024
<b>ASSETS:</b>			
<b>Non-Current Assets:</b>			
Property, Plant and Equipment	3 [A]	58,136	14,190
Capital work-in-progress	3 [D]	4,508	47,335
Other Intangible Assets	3 [B]	178	31
Financial Assets:			
Other Financial Assets	4	1	1
Deferred Tax Assets [Net]	5	842	661
Other Non-Current Assets	6	688	626
Assets for Current Tax [Net]	7	277	133
<b>Total Non-Current Assets</b>		64,630	62,977
<b>Current Assets:</b>			
Inventories	8	6,877	4,334
Financial Assets:			
Investments	9	2,877	1,831
Trade Receivables	10	4,510	2,027
Cash and Cash Equivalents	11	-	63
Other Current Assets	12	415	226
<b>Total Current Assets</b>		14,679	8,481
<b>Total Assets</b>		79,309	71,458
<b>EQUITY AND LIABILITIES:</b>			
<b>Equity:</b>			
Share Capital	13	77,000	67,000
Other Equity	14	(4,402)	(3,228)
<b>Total Equity</b>		72,598	63,772
<b>Liabilities:</b>			
<b>Non-Current Liabilities:</b>			
Financial Liabilities:			
Other Financial Liabilities	15	25	7
Provisions	16	267	155
<b>Total Non-Current Liabilities</b>		292	162
<b>Current Liabilities:</b>			
Financial Liabilities:			
Trade Payables:			
Dues to Micro and Small Enterprises	17	72	34
Dues to other than Micro and Small Enterprises	17	4,853	4,965
Other Financial Liabilities	18	1,265	2,356
Other Current Liabilities	19	101	88
Provisions	20	128	81
<b>Total Current Liabilities</b>		6,419	7,524
<b>Total Liabilities</b>		6,711	7,686
<b>Total Equity and Liabilities</b>		79,309	71,458
<b>Material Accounting Policies</b>	2		
<b>Notes to the Financial Statements</b>	3 to 40		

As per our report of even date

For Mukesh M. Shah & Co.

Chartered Accountants

Firm Registration Number:106625W

For and on behalf of the Board

sd/-

Prashant Sharma

Chairman

[DIN - 06812786]

sd/-

Vishal Shah

Whole-time Director

[DIN - 08005523]

sd/-

Karnik K Shah

Partner

Membership Number:129675

Ahmedabad, Dated : May 12, 2025

sd/-

Jignesh Thosani

Chief Financial Officer

Ahmedabad, Dated : May 12, 2025

sd/-

Dhaval Soni

Company Secretary

**ZYDUS PHARMACEUTICALS LIMITED [CIN : U24290GJ2019PLC111689]**

**Statement of Profit and Loss for the year ended March 31, 2025**

Particulars	Note No.	INR-Lakh	
		Year ended March 31	
		2025	2024
<b>INCOME:</b>			
Revenue from Operations	22	14,706	7,001
Other Income	23	169	82
<b>Total Income</b>		<b>14,875</b>	<b>7,083</b>
<b>EXPENSES:</b>			
Cost of Materials Consumed	24	4,630	3,409
Changes in Inventories of Finished goods and Work-in-progress	25	(185)	-
Employee Benefits Expense	26	4,139	2,460
Finance Costs	27	1	349
Depreciation and Amortisation Expense	3 [C]	3,942	819
Other Expenses	28	3,678	2,428
Net Loss on foreign currency transactions		2	6
<b>Total Expenses</b>		<b>16,207</b>	<b>9,471</b>
<b>Loss before Tax</b>		<b>(1,332)</b>	<b>(2,388)</b>
Less: Tax Expense:			
Current Tax	29	(6)	-
Deferred Tax	29	(177)	(264)
		<b>(183)</b>	<b>(264)</b>
<b>Loss for the year</b>		<b>(1,149)</b>	<b>(2,124)</b>
<b>OTHER COMPREHENSIVE INCOME [OCI]:</b>			
Items that will not be reclassified to profit or loss:			
Re-measurement losses on post employment defined benefit plans		(29)	(14)
Income tax effect on above		4	2
		<b>(25)</b>	<b>(12)</b>
<b>Other Comprehensive Loss for the year [Net of Tax]</b>		<b>(1,174)</b>	<b>(2,136)</b>
<b>Total Comprehensive Income for the year [Net of Tax]</b>		<b>(1,174)</b>	<b>(2,136)</b>
<b>Basic Earnings per Equity Share [EPS] [in Rupees]</b>	30	<b>(11.49)</b>	<b>(21.24)</b>
<b>Diluted Earnings per Equity Share [EPS] [in Rupees]</b>	30	<b>(1.42)</b>	<b>(4.02)</b>
<b>Material Accounting Policies</b>	2		
<b>Notes to the Financial Statements</b>	3 to 40		
<u>As per our report of even date</u>		<u>For and on behalf of the Board</u>	
For Mukesh M. Shah & Co.			
Chartered Accountants			
Firm Registration Number:106625W			
		sd/-	sd/-
		Prashant Sharma	Vishal Shah
		Chairman	Whole-time Director
		[DIN - 06812786]	[DIN - 08005523]
sd/-		sd/-	sd/-
Karnik K Shah		Jignesh Thosani	Dhaval Soni
Partner		Chief Financial Officer	Company Secretary
Membership Number:129675		Ahmedabad, Dated : May 12, 2025	
Ahmedabad, Dated : May 12, 2025			

**ZYDUS PHARMACEUTICALS LIMITED [CIN : U24290GJ2019PLC111689]**
**Cash Flow Statement for the year ended March 31, 2025**

Particulars	INR-Lakhs	
	Year ended March 31	
	2025	2024
<b>A Cash flows from operating activities:</b>		
Loss before tax	(1,332)	(2,388)
Adjustments for:		
Depreciation and Amortisation expense	3,942	819
FVTPL gain/ profit on sale of investments [Net]	(88)	(63)
Interest income	(5)	(1)
Interest expenses	-	349
Provision for doubtful advances [net of written back]	-	14
Provision for employee benefits	130	23
Total	3,979	1,141
Operating profit before working capital changes	2,647	(1,247)
Adjustments for:		
[Increase] in trade receivables	(2,483)	(1,598)
[Increase] in inventories	(2,543)	(2,926)
[Increase] in other assets	(117)	(39)
[Decrease]/Increase in trade payables	(154)	2,483
Increase in other liabilities	131	63
Total	(5,166)	(2,017)
Cash generated from operations	(2,519)	(3,264)
Income taxes paid [Net of refunds]	(138)	(106)
Net cash [used in] operating activities	(2,657)	(3,370)
<b>B Cash flows from investing activities:</b>		
Purchase of property, plant and equipment and intangible assets [including payment towards capital work-in-progress and capital advances]	(6,453)	(10,175)
Proceeds from sale of property, plant and equipment	-	6
Investments in current investments [net]	(958)	(1,768)
Interest received	5	1
Net cash [used in] investing activities	(7,406)	(11,936)
<b>C Cash flows from financing activities:</b>		
Proceeds from issuance of preference share	10,000	66,000
Proceeds from non current borrowings	-	7,285
Repayment of non current borrowings	-	(56,000)
Interest paid	-	(1,916)
Net cash from financing activities	10,000	15,369
<b>Net [decrease]/increase in cash and cash equivalents</b>	<b>(63)</b>	<b>63</b>
<b>Cash and cash equivalents at the beginning of the year</b>	<b>63</b>	<b>-</b>
<b>Cash and cash equivalents at the end of the year</b>	<b>-</b>	<b>63</b>

**Notes to the Cash Flow Statement**

- The above cash flow statement has been prepared under the "Indirect method" as set out in Ind AS-7 "Statement of Cash Flows".
- All figures in brackets are outflows.
- Summary of Cash and cash equivalents, Bank balance, Liquid Mutual funds and Fixed Deposits more than 12 months:

	INR-Lakh		
	As at March 31		
	2025	2024	2023
a Cash and cash equivalents	-	63	-
b Current Investments	2,877	1,831	-
c Total	2,877	1,894	-

As per our report of even date

For Mukesh M. Shah &amp; Co.

Chartered Accountants

Firm Registration Number:106625W

For and on behalf of the Board

sd/-

Prashant Sharma

Chairman

[DIN - 06812786]

sd/-

Vishal Shah

Whole-time Director

[DIN - 08005523]

sd/-

Karnik K Shah

Partner

Membership Number:129675

Ahmedabad, Dated : May 12, 2025

sd/-

Jignesh Thosani

Chief Financial Officer

sd/-

Dhaval Soni

Company Secretary

Ahmedabad, Dated : May 12, 2025

ZYDUS PHARMACEUTICALS LIMITED [CIN : U24290GJ2019PLC111689]		
Statement of Changes in Equity for the year ended March 31, 2025		
<b>a Equity Share Capital:</b>		
	<b>No. of Shares</b>	<b>INR-Lakh</b>
<b>Equity Shares of INR 10/- each, Issued, Subscribed and Fully Paid-up:</b>		
As at March 31, 2023	1,00,00,000	1,000
As at March 31, 2024	1,00,00,000	1,000
As at March 31, 2025	1,00,00,000	1,000
<b>8% Optionally Convertible Non Cumulative Redeemable Preference Shares (OCRPS) of INR 100/- each</b>		
As at March 31, 2023	-	-
Issued during the year	6,60,00,000	66,000
As at March 31, 2024	6,60,00,000	66,000
Issued during the year	1,00,00,000	10,000
As at March 31, 2025	7,60,00,000	76,000
<b>b Other Equity:</b>		
	<b>INR-Lakh</b>	
	<b>Retained Earnings</b>	<b>Total</b>
<b>As at March 31, 2023</b>	<b>(1,092)</b>	<b>(1,092)</b>
Less: Loss for the year	(2,124)	(2,124)
Less: Other Comprehensive loss	(12)	(12)
<b>As at March 31, 2024</b>	<b>(3,228)</b>	<b>(3,228)</b>
Add: Loss for the year	(1,149)	(1,149)
Add: Other Comprehensive loss	(25)	(25)
<b>As at March 31, 2025</b>	<b>(4,402)</b>	<b>(4,402)</b>
<div> <div> <u>As per our report of even date</u>  For Mukesh M. Shah &amp; Co.  Chartered Accountants  Firm Registration Number:106625W </div> <div> sd/-  Prashant Sharma  Chairman  [DIN - 06812786] </div> <div> sd/-  Vishal Shah  Whole-time Director  [DIN - 08005523] </div> </div> <div> sd/-  Karnik K Shah  Partner  Membership Number:129675  Ahmedabad, Dated : May 12, 2025 </div> <div> sd/-  Jignesh Thosani  Chief Financial Officer  Ahmedabad, Dated : May 12, 2025 </div> <div> sd/-  Dhaval Soni  Company Secretary  Ahmedabad, Dated : May 12, 2025 </div>		
For and on behalf of the Board		

**ZYDUS PHARMACEUTICALS LIMITED****Note: 1-Company overview:**

Zydus Pharmaceuticals Limited [hereinafter "the company"] [CIN : U24290GJ2019PLC111689], a Company limited by shares, was incorporated in India on December 26, 2019. The Company is engaged in the manufacturing, contract manufacturing and processing of Pharmaceutical products. The registered office of the Company is located at Zydus Corporate Park, Scheme No 63, Survey No 536, Khoraj [Gandhinagar], Nr Vaishnodevi Circle, S.G. Highway, Ahmedabad - 382481. These financial statements were authorised for issue in accordance with a resolution passed by the Board of Directors at their meeting held on May 12, 2025

**Note: 2-Material Accounting Policies:**

**A** The following note provides list of the Material Accounting Policies adopted in the preparation of these financial statements. These policies have been consistently applied to all the years presented unless otherwise stated.

**1 Basis of preparation:**

- A** The financial statements have been prepared in all material aspects in accordance with the Indian Accounting Standards [Ind AS] notified under section 133 of the Companies Act, 2013 read with [Indian Accounting Standards] Rules, 2015, as amended and other relevant provisions of the Companies Act, 2013.
- B** The financial statements have been prepared on historical cost basis, except for the following assets and liabilities which have been measured at fair values at the end of the reporting periods:
- i) Derivative financial instruments
  - ii) Certain financial assets and liabilities measured at fair value [refer accounting policy regarding financial instruments]
  - iii) Defined benefit plans

**2 Use of key Estimates and Judgements:**

The preparation of the financial statements in conformity with Ind AS requires management to make estimates, judgments and assumptions. These estimates, judgments and assumptions affect the application of accounting policies and the reported amounts of assets and liabilities, the disclosures of contingent assets and liabilities at the date of the financial statements and reported amounts of income and expenses during the period. Application of accounting policies that require critical accounting estimates involving complex and subjective judgments are provided below. Accounting estimates could change from period to period. Actual results could differ from those estimates. Appropriate changes in estimates are made as management becomes aware of changes in circumstances surrounding the estimates. Changes in estimates are reflected in the financial statements in the period in which changes are made and, if material, their effects are disclosed in notes to the financial statements.

**Critical accounting judgments and estimates:****A Property, Plant and Equipment:**

Property, Plant and Equipment represent a large proportion of the asset base of the Company. The charge in respect of periodic depreciation is derived after determining an estimate of an asset's expected useful life and the expected residual value at the end of its life. Management reviews the residual values, useful lives and methods of depreciation of Property, Plant and Equipment at each reporting period end and any revision to these is recognised prospectively in current and future periods. The lives are based on historical experience with similar assets as well as anticipation of future events, which may impact their lives, such as changes in technology. Refer note - 3.

**B Employee benefits:**

Actuarial valuation involves key assumptions of life expectancy, discounting rate, salary increase, etc. which significantly affect the working of the present value of future liabilities on account of employee benefits by way of defined benefit plans. Refer note - 16.

**C Taxes on Income:**

Significant judgments are involved in determining the provision for income taxes, including amount expected to be paid/ recovered for uncertain tax positions and probability of utilisation of Minimum Alternate Tax [MAT] Credit in future. Refer note - 29.

**D Contingent liabilities:**

Significant judgments are involved in determining whether there is a possible obligation, that may, but probably will not require an outflow of resources. Refer note - 21.

**3 Foreign Currency Transactions:**

The Company's financial statements are presented in Indian Rupees [INR], which is the functional and presentation currency.

- A** The transactions in foreign currencies are translated into functional currency at the rates of exchange prevailing on the dates of transactions.
- B** Foreign Exchange gains and losses resulting from settlement of such transactions and from the translation of monetary assets and liabilities denominated in foreign currencies at the year end exchange rates are recognised in the Statement of Profit and Loss.
- C** Foreign exchange differences regarded as an adjustment to borrowing costs are presented in the Statement of Profit and Loss within finance costs. All the other foreign exchange gains and losses are presented in the Statement of Profit and Loss on a net basis.

**4 Revenue Recognition:**

- A** The Company has applied Ind AS 115 - Revenue from Contracts with Customers. The following is the significant accounting policy related to revenue recognition under Ind AS 115.

**a Sale of Goods:**

Revenue from the sale of goods is recognized as revenue on the basis of customer contracts and the performance obligations contained therein. Revenue is recognised at a point in time when the control of goods or services is transferred to a customer. Control lies with the customer if the customer can independently determine the use of and consume the benefit derived from a product or service. Revenues from product deliveries are recognised at a point in time based on an overall assessment of the existence of a right to payment, the allocation of ownership rights, the transfer of significant risks and rewards and acceptance by the customer. The goods are often sold with volume discounts/ pricing incentives and customers have a right to return damaged or expired products. Revenue from sales is based on the price in the sales contracts, net of discounts, sales tax/ Goods and Services Tax [GST]. When a performance obligation is satisfied, Revenue is recognised with the amount of the transaction price [excluding estimates of variable consideration] that is allocated to that performance obligation. Historical experience, specific contractual terms and future expectations of sales returns are used to estimate and provide for damage or expiry claims. No element of financing is deemed present as the sales are made with the normal credit terms as per prevalent trade practice and credit policy followed by the Company.

**b Service Income:**

Service income is recognised as per the terms of contracts with the customers when the related services are performed as per the stage of completion or on the achievement of agreed milestones and are net of indirect taxes, wherever applicable.

**c Other Income:**

Other income is recognised when no significant uncertainty as to its determination or realisation exists.

**Note: 2-Material Accounting Policies-Continued:**

**5 Taxes on Income:**

Tax expenses comprise of current and deferred tax.

**A Current Tax:**

- a Current tax is measured at the amount expected to be paid on the basis of reliefs and deductions available in accordance with the provisions of the Income Tax Act, 1961. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted, at the reporting date.
- b Current tax items are recognised in co-relation to the underlying transaction either Profit or Loss, OCI or directly in equity.

**B Deferred Tax:**

- a Deferred tax is provided using the liability method on temporary differences between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes at the reporting date.
- b Deferred tax liabilities are recognised for all taxable temporary differences.
- c Deferred tax assets are recognised for all deductible temporary differences including the carry forward of unused tax losses. Deferred tax assets are recognised to the extent that it is probable that taxable profit will be available against which the deductible temporary differences, the carry forward of unused tax credits and unused tax losses can be utilized.
- d The carrying amount of deferred tax assets is reviewed at each reporting date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be utilized. Unrecognised deferred tax assets are re-assessed at each reporting date and are recognised to the extent that it has become probable that future taxable profits will allow the deferred tax asset to be recovered.
- e Deferred tax assets and liabilities are measured at the tax rates [and tax laws] that have been enacted or substantively enacted at the reporting date and are expected to apply in the year when the asset is realised or the liability is settled.
- f Deferred tax items are recognised in co-relation to the underlying transaction either in profit or loss, OCI or directly in equity.
- g Deferred tax assets and deferred tax liabilities are offset if a legally enforceable right exists to set off current tax assets against current tax liabilities.

**6 Property, Plant and Equipment:**

- A** Property, Plant and Equipment are stated at historical cost of acquisition/ construction less accumulated depreciation and impairment loss. Historical cost [Net of Input tax credit received/ receivable] includes related expenditure and project expenses for the period up to completion of construction/assets are ready for its intended use, if the recognition criteria are met and the present value of the expected cost for the decommissioning of an asset after its use is included in the cost of the respective asset, if the recognition criteria for a provision are met. Subsequent costs are included in the asset's carrying amount or recognised as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Company and the cost of the item can be measured reliably. The carrying amount of any component accounted for as a separate asset is derecognised when replaced. All other repairs and maintenance costs are charged to the statement of profit and loss during the reporting period in which they are incurred, unless they meet the recognition criteria for capitalisation under Property, Plant and Equipment.
- B** Where components of an asset are significant in value in relation to the total value of the asset as a whole, and they have substantially different economic lives as compared to principal item of the asset, they are recognised separately as independent items and are depreciated over their estimated economic useful lives.
- C** Depreciation on tangible assets is provided on "straight line method" based on the useful lives as prescribed under Schedule II of the Companies Act, 2013. The management believes that these estimated useful lives are realistic and reflect fair approximation of the period over which the assets are likely to be used. However, management reviews the residual values, useful lives and methods of depreciation of Property, Plant and Equipment at each reporting period end and any revision to these is recognised prospectively in current and future periods.

The estimated useful lives are as follows:

Asset Class	No. of years
Leasehold Land	Over the period of lease
Buildings	30 to 60 Years
Plant and Equipment	3 to 15 Years
Furniture, Fixtures and Office Equipments	5 to 10 Years
Vehicles	8 Years

- D** Depreciation on impaired assets is calculated on its reduced value, if any, on a systematic basis over its remaining useful life.
- E** Depreciation on additions/ disposals of the fixed assets during the year is provided on pro-rata basis according to the period during which assets are used.
- F** Where the actual cost of purchase of an asset is below INR 10,000/-, the depreciation is provided @ 100%.
- G** Capital work in progress is stated at cost less accumulated impairment loss, if any. During the years the company was engaged into construction phase and the company has capitalized all the expenditure which are directly or indirectly or ancillary to the project construction phase as capital work in progress.
- H** An item of Property, Plant and Equipment and any significant part initially recognised is derecognised upon disposal or when no future economic benefits are expected from its use/disposal. Any gain or loss arising on de-recognition of the asset [calculated as the difference between the net disposal proceeds and the carrying amount of the asset] is included in the Statement of profit and loss when the asset is derecognised.

**7 Intangible Assets:**

- A** Intangible assets acquired separately are measured on initial recognition at cost. The cost of intangible assets acquired in a business combination is their fair value at the date of acquisition. Following initial recognition, intangible assets are carried at cost less any accumulated amortisation and accumulated impairment losses.
- B** Internally generated intangibles are not capitalised and the related expenditure is reflected in the Statement of profit and loss in the period in which the expenditure is incurred.
- C** Trade Marks, Technical Know-how Fees and other similar rights are amortised over their estimated useful lives of ten years.
- D** Capitalised cost incurred towards purchase/ development of software is amortised using straight line method over its useful life of four years as estimated by the management at the time of capitalisation.

**Note: 2-Material Accounting Policies-Continued:**

- E** Intangible assets with infinite useful lives are not amortised, but are tested for impairment annually, either individually or at the cash-generating unit level. The assessment of infinite life is reviewed annually to determine whether the infinite life continues to be supportable. If not, the change in useful life from infinite to finite is made on a prospective basis.
- F** An item of intangible asset initially recognised is derecognised upon disposal or when no future economic benefits are expected from its use or disposal. Any gain or loss arising on de-recognition of the asset [calculated as the difference between the net disposal proceeds and the carrying amount of the asset] is included in the Statement of profit and loss when the asset is derecognised.

**8 Research and Development Cost:**

- A** Expenditure on research and development is charged to the Statement of Profit and Loss of the year in which it is incurred.
- B** Capital expenditure on research and development equipment is given the same treatment as Property, Plant and Equipment.

**9 Borrowing Costs:**

- A** Borrowing costs consist of interest and other borrowing costs that are incurred in connection with the borrowing of funds. Other borrowing costs include ancillary charges at the time of acquisition of a financial liability, which is recognised as per Effective Interest Rate [EIR] method. Borrowing costs also include exchange differences to the extent regarded as an adjustment to the borrowing costs.
- B** Borrowing costs that are directly attributable to the acquisition/ construction of a qualifying asset are capitalised as part of the cost of such assets, up to the date the assets are ready for their intended use. All other borrowing costs are recognised in profit or loss in the period in which they are incurred.

**10 Impairment of Non Financial Assets:**

The Property, Plant and Equipment and Intangible assets are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. Intangible assets with indefinite useful lives and intangible assets not yet available for use are tested for impairment at least annually, and whenever there is an indication that the asset may be impaired. An recoverable amount.

The recoverable amount is the higher of an asset's fair value less costs of disposal and value in use. For the purposes of assessing impairment, the assets are grouped at the lowest levels for which there are separately identifiable cash flows which are largely independent of the cash inflows from other assets or groups of assets [cash generating units]. Non-financial assets other than Goodwill that suffered an impairment loss are reviewed for possible reversal of impairment at the end of each reporting period. An impairment loss is charged to the Statement of Profit and Loss in the year in which an asset is identified as impaired. The impairment loss recognised in prior accounting period is reversed if there has been a change in the estimate of recoverable amount.

**11 Inventories:**

Inventories are valued at the lower of cost and net realisable value.

Costs incurred in bringing each product to its present location and condition are accounted for as follows:

- A** Raw Materials, Packing Materials, Finished Goods, Stock-in-Trade and Work-in-Progress are valued at lower of cost and net realisable value.
- B** Cost [Net of Input tax credit availed] of Raw Materials, Packing Materials, Finished Goods, and stock-in-trade is determined on Moving Average Method.
- C** Costs of Finished Goods and Work-in-Progress are determined by taking material cost [Net of Input tax credit availed], labour and relevant appropriate overheads based on the normal operating capacity, but excluding borrowing costs.

Net realisable value is the estimated selling price in the ordinary course of business, less estimated costs of completion and the estimated costs necessary to make the sale.

Write down of inventories to net realisable value is recognised as an expense and included in "Changes in Inventories of Finished goods, Work-in-progress and Stock-in-Trade" and "Cost of Material Consumed" in the relevant note in the Statement of Profit and Loss.

**12 Cash and Cash Equivalents:**

Cash and Cash equivalents for the purpose of Cash Flow Statement comprise cash and cheques in hand, bank balances, demand deposits with banks where the original maturity is three months or less and other short term highly liquid investments.

**13 Leases:****As a lessee:**

For any new contracts entered into on or after April 1 2019, the Company considers whether a contract is, or contains a lease. A lease is defined as 'a contract, or part of a contract, that conveys the right to use an asset [the underlying asset] for a period of time in exchange for consideration'.

**Measurement and recognition of leases as a lessee:**

At lease commencement date, the Company recognises a right-of-use asset and a lease liability on the balance sheet. The right-of-use asset is measured at cost, which is made up of the initial measurement of the lease liability, any initial direct costs incurred by the Company, an estimate of any costs to dismantle and remove the asset at the end of the lease, and any lease payments made in advance of the lease commencement date [net of any incentives received].

The Company depreciates the right-of-use assets on a straight-line basis from the lease commencement date to the earlier of the end of the useful life of the right-of-use asset or the end of the lease term. The Company also assesses the right-of-use asset for impairment when such indicators exist.

At the commencement date, the Company measures the lease liability at the present value of the lease payments unpaid at that date, discounted using the interest rate implicit in the lease if that rate is readily available or the Company's incremental borrowing rate. Lease payments included in the measurement of the lease liability are made up of fixed payments [including in substance fixed], variable payments based on an index or rate, amounts expected to be payable under a residual value guarantee and payments arising from options reasonably certain to be exercised.

Subsequent to initial measurement, the liability will be reduced for payments made and increased for interest. It is remeasured to reflect any reassessment or modification, or if there are changes to the in-substance fixed payments.

When the lease liability is remeasured, the corresponding adjustment is reflected in the right-of-use asset, or profit and loss if the right-of-use asset is already reduced to zero. The Company has elected to account for short-term leases and leases of low-value assets using the practical expedients. Instead of recognising a right-of-use asset and lease liability, the payments in relation to these are recognised as an expense in profit or loss on a straight-line basis over the lease term. On the statement of financial position, right-of-use assets have been included in property, plant and equipment and lease liabilities have been included in other financial liabilities.

**As a lessor:**

As a lessor the Company classifies its leases as either operating or finance leases. A lease is classified as a finance lease if it transfers substantially all the risks and rewards incidental to ownership of the underlying asset, and classified as an operating lease if it does not.

**Note: 2-Material Accounting Policies-Continued:****14 Provisions, Contingent Liabilities and Contingent Assets:**

- A** Provisions are recognised when the Company has a present obligation as a result of past events and it is probable that the outflow of resources will be required to settle the obligation and in respect of which reliable estimates can be made. A disclosure of contingent liability is made when there is a possible obligation, that may, but probably will not require an outflow of resources. When there is a possible obligation or a present obligation in respect of which the likelihood of outflow of resources is remote, no provision/ disclosure is made. Provisions and contingencies are reviewed at each balance sheet date and adjusted to reflect the correct management estimates. Contingent assets are not recognised but are disclosed separately in financial statements.
- B** If the effect of the time value of money is material, provisions are discounted using a current pre-tax rate that reflects, when appropriate, the risks specific to the liability.

**15 Employee Benefits:****A Short term obligations:**

Liabilities for wages and salaries, including leave encashment that are expected to be settled wholly within 12 months after the end of the period in which the employees render the related service are recognised in respect of employees' services up to the end of the reporting period and are measured by the amounts expected to be paid when the liabilities are settled. The liabilities are presented as current employee benefit obligations in the balance sheet.

**B Long term employee benefits obligations:****a Leave Wages and Sick Leave:**

The liabilities for earned leave and sick leave are not expected to be settled wholly within 12 months period after the end of the period in which the employees render the related service. They are therefore, measured at the present value of expected future payments to be made in respect of services provided by employees upto the end of the reporting period using the projected unit credit method as determined by actuarial valuation, performed by an independent actuary. The benefits are discounted using the market yields at the end of reporting period that have the terms approximating to the terms of the related obligation. Gains and losses through re-measurements are recognised in Statement of profit and loss.

**b Defined Benefit Plans - Gratuity**

The Company operates a defined benefit gratuity plan with contributions to be made to a separately administered fund through ICICI Prudential Life Insurance Company Ltd through Employees Group Gratuity Plan. The liability or asset recognised in the balance sheet in respect of defined benefit gratuity plan is the present value of the defined benefit plan obligation at the end of the reporting period less the fair value of the plan assets. The liabilities with regard to the Gratuity Plan are determined by actuarial valuation, performed by an independent actuary, at each balance sheet date using the projected unit credit method. The present value of the defined benefit obligation denominated in INR is determined by discounting the estimated future cash outflows by reference to the market yields at the reporting period on government bonds that have terms approximating to the terms of the related obligation. The net interest cost is calculated by applying the discounting rate to the net balance of the defined benefit obligation and the fair value of plan assets. Such costs are included in employee benefit expenses in the statement of Profit and Loss.

Re-measurement gains or losses arising from experience adjustments and changes in actuarial assumptions are recognised immediately in the period in which they occur directly in "other comprehensive income" and are included in retained earnings in the Statement of changes in equity and in the balance sheet. Re-measurements are not reclassified to profit or loss in subsequent periods.

The Company recognises the following changes in the net defined benefit obligation as an expense in the Statement of profit and loss:

- i Service costs comprising current service costs, past-service costs, gains and losses on curtailments and non routine settlements; and
- ii Net interest expense or income.

**c Defined Contribution Plans - Provident Fund Contribution:**

Employees of the Company, receive benefits from a provident fund, which is a defined contribution plan. Both the eligible employee and the company make monthly contributions to the provident fund plan equal to a specified percentage of the covered employee's salary. Amounts collected under the provident fund plan are deposited in a government administered provident fund. The company has no further obligation to the plan beyond their monthly contributions. Such contributions are accounted for as defined contribution plans and are recognised as employee benefits expenses when they are due in the Statement of profit and loss.

**16 Financial Instruments:**

A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.

**A Financial Assets:****a Initial recognition and measurement:**

All financial assets are recognised initially at fair value plus transaction costs, in the case of financial assets not recorded at fair value through profit or loss, that are attributable to the acquisition of the financial asset. Purchases or sales of financial assets that require delivery of assets within a time frame established by regulation or convention in the market place [regular way trades] are recognised on the settlement date, i.e., the date that the Company settles to purchase or sell the asset. However, trade receivables that do not contain a significant financing component are measured at transaction price.

**b Subsequent measurement:**

For purposes of subsequent measurement, financial assets are classified in five categories:

**i Debt instruments at amortised cost:**

A 'debt instrument' is measured at the amortised cost if both the following conditions are met:

- The asset is held with an objective of collecting contractual cash flows
- Contractual terms of the asset give rise on specified dates to cash flows that are "solely payments of principal and interest" [SPPI] on the principal amount outstanding.

After initial measurement, such financial assets are subsequently measured at amortised cost using the effective interest rate [EIR] method.

Amortised cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the EIR. The EIR amortisation is included in finance income in the Statement of Profit and Loss. The losses arising from impairment are recognised in the Statement of profit and loss.

**ii Debt instruments at fair value through other comprehensive income [FVTOCI]:**

A 'debt instrument' is classified as at the FVTOCI if both of the following criteria are met:

- The asset is held with objectives of both collecting contractual cash flows and selling the financial assets
- The asset's contractual cash flows represent SPPI.

**Note: 2-Material Accounting Policies-Continued:**

Debt instruments included within the FVTOCI category are measured initially as well as at each reporting date at fair value. Fair value movements are recognized in the OCI. However, the Company recognizes interest income, impairment losses & reversals and foreign exchange gain or loss in the Statement of Profit and Loss. On derecognition of the asset, cumulative gain or loss previously recognised in OCI is reclassified from the equity to Statement of Profit and Loss. Interest earned whilst holding FVTOCI debt instrument is reported as interest income using the EIR method.

**iii Debt instruments and derivatives at fair value through profit or loss [FVTPL]:**

FVTPL is a residual category for debt instruments. Any debt instrument, which does not meet the criteria for categorization as at amortized cost or as FVTOCI, is classified as at FVTPL.

Instruments included within the FVTPL category are measured at fair value with all changes recognized in the Statement of Profit and Loss.

**c Derecognition:**

A financial asset [or, where applicable, a part of a financial asset] is primarily derecognised [i.e. removed from the Company's balance sheet] when:

- i The rights to receive cash flows from the asset have expired, or
- ii The Company has transferred its rights to receive cash flows from the asset or has assumed an obligation to pay the received cash flows in full without material delay to a third party under a 'pass-through' arrangement; and either [a] the Company has transferred substantially all the risks and rewards of the asset, or [b] the Company has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset.

When the Company has transferred its rights to receive cash flows from an asset or has entered into a pass-through arrangement, it evaluates if and to what extent it has retained the risks and rewards of ownership. When it has neither transferred nor retained substantially all of the risks and rewards of the asset, nor transferred control of the asset, the Company continues to recognise the transferred asset to the extent of the Company's continuing involvement. In that case, the Company also recognises an associated liability. The transferred asset and the associated liability are measured on a basis that reflects the rights and obligations that the Company has retained. When the Company has transferred the risks and rewards of ownership of the financial asset, the same is derecognised.

**d Impairment of financial assets:**

In accordance with Ind AS 109, the Company applies expected credit loss [ECL] model for measurement and recognition of impairment loss on trade receivables or any contractual right to receive cash or another financial asset.

The Company follows 'simplified approach' for recognition of impairment loss allowance for trade receivables or any contractual right to receive cash or another financial asset. The application of simplified approach does not require the Company to track changes in credit risk. Rather, it requires the Company to recognise the impairment loss allowance based on lifetime ECLs at each reporting date, right from its initial recognition. For recognition of impairment loss on other financial assets and risk exposure, the Company determines that whether there has been a significant increase in the credit risk since initial recognition. If credit risk has not increased significantly, 12-month ECL is used to provide for impairment loss.

However, if credit risk has increased significantly, lifetime ECL is used. If, in a subsequent period, credit quality of the instrument improves such that there is no longer a significant increase in credit risk since initial recognition, then the entity reverts to recognising impairment loss allowance based on 12-month ECL. Lifetime ECL are the expected credit losses resulting from all possible default events over the expected life of a financial instrument. The 12-month ECL is a portion of the lifetime ECL which results from default events that are possible within 12 months after the reporting date.

ECL is the difference between all contractual cash flows that are due to the Company in accordance with the contract and all the cash flows that the entity expects to receive [i.e., all cash shortfalls], discounted at the original EIR.

ECL impairment loss allowance [or reversal] is recognized as expense/ income in the Statement of profit and loss. The balance sheet presentation for various financial instruments is described below:

Financial assets measured as at amortised cost and contractual revenue receivables: ECL is presented as an allowance, i.e., as an integral part of the measurement of those assets in the balance sheet, which reduces the net carrying amount. Until the asset meets write-off criteria, the Company does not reduce impairment allowance from the gross carrying amount.

For assessing increase in credit risk and impairment loss, the Company combines financial instruments on the basis of shared credit risk characteristics.

**B Financial Liabilities:****a Initial recognition and measurement:**

Financial liabilities are classified, at initial recognition, as financial liabilities at fair value through profit or loss, loans and borrowings, payables, or as derivatives designated as hedging instruments in an effective hedge, as appropriate. All financial liabilities are recognised initially at fair value and, in the case of loans and borrowings and payables, net of directly attributable transaction costs.

**b Subsequent measurement:**

Subsequently all financial liabilities are measured as amortised cost, using EIR method. Gains and losses are recognised in Statement of profit and loss when the liabilities are derecognised as well as through the EIR amortisation process. Amortised cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the EIR. The EIR amortisation is included as finance costs in the Statement of profit and loss.

**c Derecognition:**

A financial liability is derecognised when the obligation under the liability is discharged or cancelled or expires. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as the derecognition of the original liability and the recognition of a new liability. The difference in the respective carrying amounts is recognised in the Statement of profit and loss.

**C Reclassification of financial assets:**

The Company determines classification of financial assets and liabilities on initial recognition. After initial recognition, no reclassification is made for financial assets which are equity instruments and financial liabilities. For financial assets which are debt instruments, a reclassification is made only if there is a change in the business model for managing those assets. Changes to the business model are expected to be infrequent. The Company's senior management determines change in the business model as a result of external or internal changes which are significant to the Company's operations. Such changes are evident to external parties. A change in the business model occurs when the Company either begins or ceases to perform an activity that is significant to its operations. If the Company reclassifies financial assets, it applies the reclassification prospectively from the reclassification date which is the first day of the immediately next reporting period following the change in business model as per Ind AS 109.

**D Offsetting of financial instruments:**

Financial assets and financial liabilities are offset and the net amount is reported in the balance sheet if there is a currently enforceable legal right to offset the recognised amounts and there is an intention to settle on a net basis, to realise the assets and settle the liabilities simultaneously.

**Note: 2-Material Accounting Policies-Continued:****17 Fair Value Measurement:**

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either:

- a In the principal market for the asset or liability, or
- b In the absence of a principal market, in the most advantageous market for the asset or liability

The principal or the most advantageous market must be accessible by the Company.

The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest.

A fair value measurement of a non-financial asset takes into account a market participant's ability to generate economic benefits by using the asset in its highest and best use or by selling it to another market participant that would use the asset in its highest and best use. The Company uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value. All assets and liabilities for which fair value is measured or disclosed in the financial statements are categorised within the fair value hierarchy, described as follows, based on the lowest level input that is significant to the fair value measurement as a whole:

- a Level 1 — Quoted [unadjusted] market prices in active markets for identical assets or liabilities
- b Level 2 — Valuation techniques for which the lowest level input that is significant to the fair value measurement is directly or indirectly observable
- c Level 3 — Valuation techniques for which the lowest level input that is significant to the fair value measurement is unobservable

For assets and liabilities that are recognised in the financial statements on a recurring basis, the Company determines whether transfers have occurred between levels in the hierarchy by re-assessing categorisation [based on the lowest level input that is significant to the fair value measurement as a whole] at the end of each reporting period.

**18 Earnings per Share:**

Basic earnings per share is calculated by dividing the net profit or loss [excluding other comprehensive income] for the year attributable to equity shareholders by the weighted average number of equity shares outstanding during the year. The weighted average number of equity shares outstanding during the year is adjusted for events such as bonus issue, bonus element in a right issue, shares split and reserve share splits [consolidation of shares] that have changed the number of equity shares outstanding, without a corresponding change in resources. For the purpose of calculating diluted earnings per share, the net profit or loss [excluding other comprehensive income] for the year attributable to equity shareholders and the weighted average number of shares outstanding during the year are adjusted for the effects of all dilutive potential equity shares.

**B Recent Accounting Pronouncements:**

The Ministry of Corporate Affairs [MCA] notifies new standards or amendments to the existing standards under Companies [Indian Accounting Standards] Rules as issued from time to time. During the year ended March 31, 2025, MCA has notified amendments to Ind AS 116 – Leases relating to sale and lease back transactions, applicable from April 1, 2024. The Company has reviewed the new amendments and based on evaluation there is no significant impact on its financial statements.

On May 7, 2025, MCA notifies the amendments to Ind AS 21 - Effects of Changes in Foreign Exchange Rates. These amendments aim to provide clearer guidance on assessing currency exchangeability and estimating exchange rates when currencies are not readily exchangeable. The amendments are effective for the year beginning from April 1, 2025. The Company has reviewed the new amendments and based on evaluation there is no significant impact on its financial statements.

**ZYDUS PHARMACEUTICALS LIMITED**

**Notes to the Financial Statements**

**Note: 3-Property, Plant and Equipment, Intangible Assets & Capital work-in-progress [CWIP]:**

[A] Property, Plant and Equipment:

[A] Property, Plant and Equipment:							INR-Lakh
	Leasehold <u>Land *</u>	<u>Buildings</u>	Plant and <u>Equipment</u>	Furniture and <u>Fixtures</u>	<u>Vehicles</u>	Office <u>Equipment</u>	<u>Total</u>
Gross Block:							
As at March 31, 2023	4,431	5,551	5,500	125	22	112	15,741
Additions	-	-	-	-	-	-	-
Disposals	-	-	-	-	(8)	-	(8)
As at March 31, 2024	4,431	5,551	5,500	125	14	112	15,733
Additions	-	10,241	36,702	779	47	72	47,841
Disposals	-	-	-	-	-	-	-
As at March 31, 2025	4,431	15,792	42,202	904	61	184	63,574
Depreciation and Impairment:							
As at March 31, 2023	111	124	454	9	1	17	716
Depreciation for the year	45	176	572	12	3	21	829
Disposals	-	-	-	-	(2)	-	(2)
As at March 31, 2024	156	300	1,026	21	2	38	1,543
Depreciation for the year	45	423	3,323	69	5	30	3,895
Disposals	-	-	-	-	-	-	-
As at March 31, 2025	201	723	4,349	90	7	68	5,438
Net Block:							
As at March 31, 2024	4,275	5,251	4,474	104	12	74	14,190
As at March 31, 2025	4,230	15,069	37,853	814	54	116	58,136

[B] Intangible Assets:

	Other Intangible Assets	
	<u>Computer Software</u>	<u>Total</u>
Gross Block:		
As at March 31, 2023	56	<b>56</b>
Additions	-	-
Disposals	-	-
As at March 31, 2024	56	<b>56</b>
Additions	198	<b>198</b>
Disposals	-	-
As at March 31, 2025	254	<b>254</b>
Amortisation and Impairment:		
As at March 31, 2023	11	<b>11</b>
Amortisation for the year	14	<b>14</b>
Disposals	-	-
As at March 31, 2024	25	<b>25</b>
Amortisation for the year	51	<b>51</b>
Disposals	-	-
As at March 31, 2025	76	<b>76</b>
Net Block:		
As at March 31, 2024	31	<b>31</b>
As at March 31, 2025	178	<b>178</b>

[\*] Includes right of use assets, refer Note-36 for detailed breakup.

[C] Depreciation and Amortisation Expenses:

	INR-Lakh	
	Year ended March 31	
	2025	2024
Depreciation	<b>3,895</b>	829
Amortisation	<b>51</b>	14
<b>Total</b>	<b>3,946</b>	843
Depreciation transfer to CWIP	<b>4</b>	24
Net Depreciation charged to P&L	<b>3,942</b>	819

**ZYDUS PHARMACEUTICALS LIMITED**

**Notes to the Financial Statements**

**Note: 3-Property, Plant and Equipment, Intangible Assets & Capital work-in-progress-Continued:**

[D] Capital Work in Progress[Net]:	INR-Lakh	
	Year ended March 31	
	2025	2024
Opening balance	47,335	37,936
<b>Addition for the year:</b>		
Other Property, Plant and Equipments	4,723	6,392
Depreciation on Right to use assets	4	24
Finance Costs	-	876
Other Expenses	46	283
Consumption Of Materials	203	380
Power and Fuel	96	735
Salaries & Wages	140	752
Other Income	-	(43)
Total	52,547	47,335
Capitalized during the year	(48,039)	-
<b>Total</b>	<b>4,508</b>	<b>47,335</b>

[E] Ageing of Capital-work-in progress:

A Projects in progress:		
a Less than 1 year	2,505	9,399
b 1 - 2 years	1,993	24,898
c 2 - 3 years	10	12,169
d More than 3 years	-	869
Total Capital Work-in-Progress	4,508	47,335
There are no overdue or temporary suspended projects.		
Project execution plans are modulated on the basis of capacity requirement assessment annually and all the projects are executed based on rolling annual plan.		

**Note: 4-Other Financial Assets:**

[Unsecured, Considered Good unless otherwise stated]		
Security Deposits	1	1
<b>Total</b>	<b>1</b>	<b>1</b>

**Note: 5-Deferred Tax:**

**A** Break up of Deferred Tax Liabilities and Assets into major components of the respective balances are as under:

	INR-Lakh			
	As at March 31 2023	Impact for the current year	As at March 31 2024	Impact for the current year
Deferred Tax Liabilities:				
Property, Plant and Equipment	235	27	262	678
	235	27	262	678
Deferred Tax Assets:				
Employee benefits/ Payable to Statutory Authorities	29	6	35	19
Receivables	-	2	2	2
Unabsorbed depreciation and Business loss	599	286	884	839
Others	3	(1)	2	(1)
	631	293	923	859
<b>Net Deferred Tax Assets</b>	<b>396</b>	<b>266</b>	<b>661</b>	<b>181</b>

**B** The Net Deferred Tax asset of INR 181 Lakh [Previous Year INR 266 Lakhs] has been recognised in the Statement of Profit and Loss.

**C** The Company offsets tax assets and liabilities if and only if it has a legally enforceable right to set off current tax assets and current tax liabilities and the deferred tax assets and deferred tax liabilities relate to income taxes levied by the same tax authority.

Followings are the details of tax losses available for set-off against future taxable profit.

INR-Lakh			
Particulars	Tax losses set off upto Financial Year	As at March 31 2024	As at March 31 2025
Business Loss	2030-31	867	867
Business Loss	2031-32	1,259	1,259
Unabsorbed depreciation	Indefinite period	2,808	7,917
<b>Total</b>		<b>4,934</b>	<b>10,043</b>

**Note: 6-Other Non-Current Assets:**

[Unsecured, Considered Good unless otherwise stated]		
Capital Advances - Considered Good	674	619
Capital Advances - Credit impaired	14	14
	688	633
Less: Allowances for credit impaired	14	14
	674	619
Others	14	7
<b>Total</b>	<b>688</b>	<b>626</b>

**ZYDUS PHARMACEUTICALS LIMITED**  
**Notes to the Financial Statements**

		INR-Lakh					
		As at March 31					
		2025	2024				
<b>Note: 7-Assets for Current Tax:</b>							
Advance payment of Tax		277	133				
<b>Total</b>		277	133				
<b>Note: 8-Inventories:</b>							
[The Inventory is valued at lower of cost and net realisable value]							
Classification of Inventories:							
Raw Materials		6,443	3,997				
Work-in-progress		17	185				
Finished Goods		168	-				
Others:							
Packing Materials		249	152				
<b>Total</b>		6,877	4,334				
The above includes Goods in transit as under:							
Raw Materials		-	11				
<b>Note: 9-Investments [Current]:</b>							
Investment in Mutual Funds [Quoted] [Valued at fair value through profit or loss] ICICI Prudential Liquid Fund - Direct Plan - Growth ICICI Prudential Overnight Fund - Direct Plan - Growth <b>Total</b> [*] In "Nos." figures of previous year are stated in [ ].	<b>Nos. [*]</b>						
	7,49,485.180 [Nil]	2,877					
	Nil [1,41,870.604]		1,831				
		2,877	1,831				
<b>Note: 10-Trade Receivables:</b>							
Unsecured- Considered good		4,510	2,027				
		4,510	2,027				
Less: Allowances for credit losses		-	-				
<b>Total</b>		4,510	2,027				
<b>Ageing of Trade Receivables:</b>							
		INR-Lakh					
Particulars	Not due	Outstanding from due date of payment					Total
		Less than 6 Months	6 Months to 1 year	1 to 2 years	2 to 3 years	More than 3 years	
		As at March 31, 2025					
Undisputed – considered good	4,427	83	-	-	-	-	4,510
Undisputed – have significant increase in credit risk	-	-	-	-	-	-	-
Undisputed – credit impaired	-	-	-	-	-	-	-
Disputed – considered good	-	-	-	-	-	-	-
Disputed - have significant increase in credit risk	-	-	-	-	-	-	-
Disputed - credit impaired	-	-	-	-	-	-	-
Total	4,427	83	-	-	-	-	4,510
Less: Allowances for credit losses	-	-	-	-	-	-	-
Trade Receivables							4,510
		As at March 31, 2024					
Undisputed – considered good	2,009	18	-	-	-	-	2,027
Undisputed – have significant increase in credit risk	-	-	-	-	-	-	-
Undisputed – credit impaired	-	-	-	-	-	-	-
Disputed – considered good	-	-	-	-	-	-	-
Disputed - have significant increase in credit risk	-	-	-	-	-	-	-
Disputed - credit impaired	-	-	-	-	-	-	-
Total	2,009	18	-	-	-	-	2,027
Less: Allowances for credit losses							-
Trade Receivables							2,027
<b>Note: 11-Cash and Bank Balances:</b>							
<b>Cash and Cash Equivalents:</b>							
Balances with Banks				-	63		
<b>Total</b>				-	63		
There are no amounts of cash and cash equivalent balances held by the entity that are not available for use.							

**ZYDUS PHARMACEUTICALS LIMITED**  
**Notes to the Financial Statements**

					INR-Lakh	
					As at March 31	
					2025	2024
<b>Note: 12-Other Current Assets:</b>						
[Unsecured, Considered Good, unless otherwise stated]						
Balances with Statutory Authorities					8	5
Advances to Suppliers - Considered Good					257	205
Prepaid Expenses					122	3
Others					28	13
<b>Total</b>					<b>415</b>	<b>226</b>
<b>Note: 13- Share Capital:</b>						
<b>Authorised:</b>						
10,000,000 [As at March 31, 2024: 10,000,000 ] Equity Shares of INR 10/- [INR 10/-] each					1,000	1,000
79,000,000 [as at March 31, 2024: 69,000,000] 8% Optionally Convertible Non Cumulative Redeemable Preference Shares [OCRPS] of INR 100/- [INR 100/-] each					79,000	69,000
					<b>80,000</b>	<b>70,000</b>
<b>Issued, Subscribed and Paid-up:</b>						
10,000,000 [As at March 31, 2024: 10,000,000 ] Equity Shares of INR 10/- [INR 10/-] each, fully paid up					1,000	1,000
76,000,000 [As at March 31, 2024: 66,000,000 ] 8% Optionally Convertible Non Cumulative Redeemable Preference Shares [OCRPS] of INR 100/- [INR 100/-] each, fully paid up					76,000	66,000
<b>Total</b>					<b>77,000</b>	<b>67,000</b>
A There is no change in the number of equity shares as at the beginning and end of the year.						
Number of shares at the beginning and end of the year					1,00,00,000	1,00,00,000
Number of 8% Optionally Convertible Non Cumulative Redeemable Preference Shares at the beginning of the year					6,60,00,000	-
Add: Shares Issued during the year					1,00,00,000	6,60,00,000
Number of 8% Optionally Convertible Non Cumulative Redeemable Preference Shares at the end of the year					7,60,00,000	6,60,00,000
B The Company has only one class of equity shares having a par value of INR 10/- per share. Each holder of equity share is entitled to one vote per share. The dividend proposed by the Board of Directors is subject to the approval of the shareholders in the Annual General Meeting, except in the case of interim dividend. In the event of liquidation of the Company, the equity shareholders shall be entitled to proportionate share of their holding in the assets remaining after distribution of all preferential amounts.						
C Optionally Convertible Non Cumulative Redeemable Preference Shares [OCRPS] are redeemable at par. At anytime during the tenure of the OCRPS, the Issuer of the OCRPS shall have right to have all, or any part, of the OCRPS to be converted as Equity Shares. Such conversion shall happen at a pre-determined agreed rate between the parties. The tenure of the OCRPS shall be 20 years from the date of allotment. At any time during the tenure of the OCRPS, the Company shall have a right to redeem, all or any part of outstanding OCRPS. The OCRPS shall carry a preferential right with respect to dividend on the paid up capital in the event of distribution of profits by the company.						
D Details of Shareholder holding more than 5% of aggregate Equity Shares of INR 10/- each:						
Zydus Lifesciences Limited and its nominees						
Number of Shares					1,00,00,000	1,00,00,000
% to total share holding					100%	100%
E All the OCRPS of INR 100/- each, fully paid up held by Holding Company, Zydus Lifesciences Limited:						
Number of Shares					7,60,00,000	6,60,00,000
% to total share holding					100%	100%
F Equity Shares held by the promoters/ promoter group of the Company as at the end of the year March 31, 2025 and 2024:						
	<b>Promoter's/ Promoter Group's Name</b>	<b>No. of Shares</b>	<b>% of total shares</b>	<b>% change during the year</b>		
1	Zydus Lifesciences Limited and it's Nominees	1,00,00,000	100%	-		
<b>Note: 14-Other Equity:</b>						
<b>Retained Earnings:</b>						
Balance as per last Balance Sheet					(3,228)	(1,092)
Add: Loss for the year					(1,149)	(2,124)
					<b>(4,377)</b>	<b>(3,216)</b>
Less: Items of other Comprehensive income recognised directly in Retained Earnings:						
Re-measurement gains/ [losses] on defined benefit plans [net of tax]					(25)	(12)
Balance as at the end of the year					<b>(4,402)</b>	<b>(3,228)</b>
<b>Total</b>					<b>(4,402)</b>	<b>(3,228)</b>
<b>Note: 15-Other Financial Liabilities:</b>						
Security Deposits					25	7
<b>Total</b>					<b>25</b>	<b>7</b>

**ZYDUS PHARMACEUTICALS LIMITED**  
**Notes to the Financial Statements**

	<b>INR-Lakh</b>	
	<b>As at March 31</b>	
	<b>2025</b>	<b>2024</b>
<b>Note: 16-Provisions:</b>		
Provision for Employee Benefits	<b>267</b>	155
<b>Total</b>	<b>267</b>	155

**Defined benefit plan and long term employment benefit**

**A General description:**

**Leave wages [Long term employment benefit]:**

The employees of the company are entitled to leave as per the leave policy of the company. The liability on account of accumulated leave as on last day of the accounting year is recognised at present value of the defined obligation at the balance sheet date based on the actuarial valuation carried out by an independent actuary using projected unit credit method

**Gratuity [Defined benefit plan]:**

The Company has a defined benefit gratuity plan. Every employee who has completed continuous services of five years or more gets a gratuity on death or resignation or retirement at 15 days salary [last drawn salary] for each completed year of service. The scheme is funded with an insurance company in the form of a qualifying insurance policy.

The plans typically expose the Company to actuarial risks such as: investment risk, interest rate risk, longevity risk and salary increment risk.

**Investment risk:**

The present value of the defined benefit plan liability is calculated using a discount rate which is determined by reference to market yields at the end of the reporting period on government bonds.

**Interest risk:**

A decrease in the bond interest rate will increase the plan liability; however, this will be partially offset by an increase in the return on the plan's debt investments.

**Longevity risk:**

The present value of the defined benefit plan liability is calculated by reference to the best estimate of the mortality of plan participants both during and after their employment. An increase in the life expectancy of the plan participants will increase the plan's liability.

**Salary risk:**

The present value of the defined benefit plan liability is calculated by reference to the future salaries of plan participants. As such, an increase in the salary of the plan participants will increase the plan's liability.

**INR-Lakh**  
**As at March 31**

**B Change in the present value of the defined benefit obligation:**

	<b>2025</b>			<b>2024</b>		
	<u>Medical Leave</u>	<u>Leave Wages</u>	<u>Gratuity</u>	<u>Medical Leave</u>	<u>Leave Wages</u>	<u>Gratuity</u>
Opening obligation	10	194	128	6	117	76
Transfer in/ (out) Obligation	-	14	13	-	1	-
Interest cost	-	12	9	1	8	5
Current service cost	3	75	59	3	46	33
Benefits paid	-	(18)	-	-	(23)	-
Actuarial [gains]/ losses on obligation due to:						
Experience adjustments	(1)	30	17	-	43	11
Change in financial assumptions	1	10	12	-	2	3
Closing obligation	13	317	238	10	194	128

**C Change in the fair value of plan assets:**

Opening fair value of plan assets	-	-	96	-	-	-
Transfer in/ (out) Assets	-	-	-	-	-	-
Interest Income	-	-	8	-	-	1
Return on planned assets	-	-	(1)	-	-	-
Contributions by employer	-	-	70	-	-	95
Benefits paid	-	-	-	-	-	-
Closing fair value of plan assets	-	-	173	-	-	96
<b>Total actuarial [losses] / gains to be recognised</b>	-	(40)	(30)	-	45	14

**D Actual return on plan assets:**

Expected return on plan assets	-	-	7	-	-	1
Actual return on plan assets	-	-	7	-	-	1

**E Amount recognised in the balance sheet:**

Liabilities/ [Assets] at the end of the year	13	317	238	10	194	128
Fair value of plan assets at the end of the year	-	-	(173)	-	-	(96)
Liabilities/ [Assets] recognised in the Balance Sheet	13	317	65	10	194	32

**ZYDUS PHARMACEUTICALS LIMITED**  
**Notes to the Financial Statements**

**Note: 16-Long Term Provisions-Continued:**

	INR-Lakh					
	As at March 31					
	2025			2024		
	Medical Leave	Leave Wages	Gratuity	Medical Leave	Leave Wages	Gratuity
F Expenses/ [Incomes] recognised in the Statement of Profit and Loss:						
Current service cost	3	75	59	3	46	33
Interest cost on benefit obligation	-	12	9	1	8	5
Expected return on plan assets	-	-	-	-	-	-
Return on plan assets excluding amounts included in interest income	-	-	(8)	-	-	-
Net actuarial [gains]/ losses in the year	-	40	-	-	45	-
Amount included in "Employee Benefits Expense"	3	127	60	4	99	38
Return on plan assets excluding amounts included in interest income	-	-	-	-	-	-
Net actuarial [gains]/ losses in the year	-	-	30	-	-	14
Amounts recognized in OCI	-	-	30	-	-	14
G Movement in net liabilities recognised in Balance Sheet:						
Opening net liabilities	10	194	32	6	117	76
Transfer in/ (out) Obligation	-	14	13	-	1	-
Expenses as above [P & L Charge]	3	127	60	4	99	38
Employer's contribution	-	-	-	-	-	-
Amount recognised in OCI	-	-	30	-	-	14
Benefits Paid	-	(18)	-	-	(23)	-
Contribution to plan assets	-	-	(70)	-	-	(96)
Liabilities/ [Assets] recognised in the Balance Sheet	13	317	65	10	194	32
H Principal actuarial assumptions for defined benefit plan and long term employment benefit plan:						
Discount rate	6.65%	6.65%	6.65%	7.20%	7.20%	7.20%
[The rate of discount is considered based on market yield on Government Bonds having currency and terms in consistence with the currency and terms of the post employment benefit obligations]						
Annual increase in salary cost	12% for next 2 year, 9% thereafter			12% for next 2 year, 9% thereafter		
[The estimates of future salary increases are considered in actuarial valuation, taking into account inflation, seniority, promotion and other relevant factors such as supply and demand in the employment market]						
Withdrawal rates [p.a.]	40% at younger ages reducing to 1% at older ages			40% at younger ages reducing to 1% at older ages		
[The estimates of level of attrition is based on broad economic outlook, type of sector the Company operates in and measures taken by the management to retain/ relieve the employees]						
I The categories of plan assets as a % of total plan assets are:						
Insurance plan	0.00%	0.00%	100%	0.00%	0.00%	100.00%
The expected contributions for Defined Benefit Plan for the next financial year will be INR 65 Lakh [Previous year 33 Lakhs].						
The weighted average duration of the defined benefit plan obligation at the end of the reporting period is 8.02 years [as at March 31, 2024: 8.52 years].						

**Sensitivity analysis:**

A quantitative sensitivity analysis for significant assumptions is shown below:

Assumptions	INR-Lakh					
	Medical Leave		Leave Wages		Gratuity	
	As at March 31					
	2025	2024	2025	2024	2025	2024
Impact on obligation:						
Discount rate increase by 0.5%	(1)	(1)	(9)	(5)	(10)	(6)
Discount rate decrease by 0.5%	1	1	10	6	12	7
Annual salary cost increase by 0.5%	1	1	10	6	12	6
Annual salary cost decrease by 0.5%	(1)	(1)	(9)	(5)	(10)	(6)
Withdrawal rate increase by 10%	(1)	(1)	(6)	(3)	(9)	(5)
Withdrawal rate decrease by 10%	1	1	7	4	11	5

**The following payments are expected contributions to the defined benefit plan in future years:**

	<b>INR-Lakh</b>	
	<b>As at March 31</b>	
	<b>2025</b>	2024
Within the next 12 months [next annual reporting period]	72	49
Between 2 and 5 years	217	126
Between 6 and 10 years	174	101
<b>Total expected payments</b>	<b>463</b>	<b>276</b>

**ZYDUS PHARMACEUTICALS LIMITED**  
**Notes to the Financial Statements**

						INR-Lakh	
						As at March 31	
						2025	2024
<b>Note: 17-Trade Payables:</b>							
Dues to Micro and Small Enterprises [*]						72	34
Dues to other than Micro and Small Enterprises						4,853	4,965
<b>Total</b>						4,925	4,999
[*] Disclosure in respect of Micro and Small Enterprises:							
A Principal amount remaining unpaid to any supplier as at year end						72	34
B Interest due thereon						-	-
C Amount of interest paid by the Company in terms of section 16 of the MSMED Act, along with the amount of the payment made to the supplier beyond the appointed day during the year						3	1
D Amount of interest due and payable for the year of delay in making payment [which have been paid but beyond the appointed day during the year] but without adding the interest specified under the MSMED Act						-	-
E Amount of interest accrued and remaining unpaid at the end of the accounting year						-	-
F Amount of further interest remaining due and payable in succeeding years						-	-
The above information has been compiled in respect of parties to the extent to which they could be identified as Micro and Small Enterprises on the basis of information available with the Company.							
<b>Ageing of Trade Payables :</b>						<b>INR-Lakh</b>	
Particulars	Not Due	Outstanding from due date of payment				Total	
		Less than 1 year	1 to 2 years	2 to 3 years	More than 3 years		
<b>As at March 31, 2025</b>							
Undisputed Micro and Small Enterprises [MSME]	45	25	2	-	-	72	
Undisputed Others	2,645	1,321	884	1	2	4,853	
Disputed MSME	-	-	-	-	-	-	
Disputed Others	-	-	-	-	-	-	
<b>Total</b>	2,690	1,346	886	1	2	4,925	
<b>As at March 31, 2024</b>							
Undisputed Micro and Small Enterprises [MSME]	34	-	-	-	-	34	
Undisputed Others	1,186	3,770	4	4	1	4,965	
Disputed MSME	-	-	-	-	-	-	
Disputed Others	-	-	-	-	-	-	
<b>Total</b>	1,220	3,770	4	4	1	4,999	
<b>Note: 18-Other Financial Liabilities:</b>							
Book Overdraft						13	-
Accrued Expenses						373	287
Payable for Capital Goods						879	2,069
<b>Total</b>						1,265	2,356
<b>Note: 19-Other Current Liabilities:</b>							
Advances from Customers [as at March 31,2025 INR 21,516 {as at March 31,2024 INR 23,755}]						-	-
Payable to Statutory Authorities						93	79
Others						8	9
<b>Total</b>						101	88
<b>Note: 20-Provisions:</b>							
Provision for Employee Benefits						128	81
<b>Total</b>						128	81
<b>Note: 21-Contingent Liabilities and Commitments [to the extent not provided for]:</b>							
<b>A Commitments:</b>							
a Estimated amount of contracts remaining to be executed on capital account and not provided for						3,740	1,836
- Net of advance of						677	410
<b>B Contingent Liabilities:</b>						-	-
<b>Note: 22-Revenue from Operations:</b>							
Sale of Products						591	-
Other Operating Revenues:							
Contract manufacturing and processing income						14,048	6,943
Miscellaneous Income						67	58
<b>Total</b>						14,706	7,001
Pursuant to Ind AS 115 "Revenue from Contracts with Customers" reconciliation of revenue recognised in the statement of profit and loss with the contracted price is under:							
Revenue as per contracted price						591	-
Less:							
Provision for Expiry and Sales Return						-	-
Discounts/ Price Reduction/ Rebates/ Other adjustments						-	-
<b>Revenue from contract with customers</b>						591	-

**ZYDUS PHARMACEUTICALS LIMITED**  
**Notes to the Financial Statements**

	INR-Lakh	
	Year ended March 31	
	2025	2024
<b>Note: 23-Other Income:</b>		
Finance Income:		
Interest Income on Financial Assets measured at Amortised Cost [as at March 31,2025: INR 700 {as at March 31,2024: INR 677}]	-	-
	-	-
Gain on Investments mandatorily measured at FVTPL	88	63
Other Income	81	19
<b>Total</b>	<b>169</b>	<b>82</b>
<b>Note: 24-Cost of Materials Consumed:</b>		
Cost of Materials Consumed towards supply of Services	4,266	3,409
Cost of Materials Consumed in respect of supply of Goods	364	-
<b>Total</b>	<b>4,630</b>	<b>3,409</b>
<b>Note: 25-Changes in Inventories:</b>		
Stock at commencement:		
Work-in-progress	-	-
Finished Goods	-	-
	-	-
Less: Stock at close:		
Work-in-progress	17	-
Finished Goods	168	-
	185	-
<b>Total</b>	<b>(185)</b>	<b>-</b>
<b>Note: 26-Employee Benefits Expense:</b>		
Salaries and wages	3,683	2,243
Contribution to provident and other funds [*]	284	159
Staff welfare expenses	172	58
<b>Total</b>	<b>4,139</b>	<b>2,460</b>
[*] The Company's contribution towards defined contribution plan: The Company makes Provident Fund contributions to defined contribution plans for qualifying employees, as specified under the law. The contributions are paid to the respective Regional Provident Fund Commissioner under the Pension Scheme.	209	119
<b>Note: 27-Finance Cost:</b>		
Interest expense on loan from related parties	-	349
Bank commission & charges [as at March 31,2024: INR 36,239/-]	1	-
<b>Total</b>	<b>1</b>	<b>349</b>
<b>Note: 28-Other Expenses:</b>		
Consumption of Stores and spare parts	1,072	624
Power & fuel	936	446
Water charges	368	398
Analytical Expenses	43	80
Repairs to Buildings	45	46
Repairs to Plant and Machinery	180	163
Repairs to Others	32	21
Insurance	112	40
Traveling Expenses	14	4
Legal and Professional Fees [*]	122	269
Allowance for Doubtful Advances:		
Allowance for credit impaired	-	14
Miscellaneous Expenses	754	323
<b>Total</b>	<b>3,678</b>	<b>2,428</b>
[*] Legal and Professional Fees include: Payment to the Statutory Auditors [excluding GST]:		
- As Auditor	2	2
- For Other Services	1	1
- Total	3	3

**ZYDUS PHARMACEUTICALS LIMITED**  
**Notes to the Financial Statements**

		INR-Lakh	
		Year ended March 31	
		2025	2024
<b>Note: 29-Tax Expenses:</b>			
<b>The major components of income tax expense are:</b>			
<b>A Statement of profit and loss:</b>			
<b>Profit or loss section:</b>			
<b>Current income tax:</b>			
Current income tax charge		-	-
Adjustments in respect of current income tax of previous years		(6)	-
		(6)	-
<b>Deferred tax:</b>			
Relating to origination and reversal of temporary differences [Refer Note-5]		(177)	(264)
		(183)	(264)
<b>Tax expense reported in profit or loss</b>			
<b>OCI Section:</b>			
Tax related to items recognised in OCI during in the year:			
Net loss on re-measurements of defined benefit plans		4	2
Tax charged to OCI		4	2
<b>B Reconciliation of tax expense and accounting profit multiplied by India's domestic tax rate:</b>			
Profit before tax		(1,332)	(2,388)
Enacted Tax Rate in India (%)		17.16%	17.16%
Expected Tax Expenses		(229)	(410)
Adjustments for:			
Tax effect due to non-taxable income for tax purposes		(2)	(1)
Effect of non-deductible expenses		1	2
Effect of unrecognised excess deferred tax assets/liabilities		53	143
Effect of current income tax of previous years		(6)	-
Total		46	144
<b>Tax Expenses as per Profit or Loss</b>		(183)	(266)
<b>Note: 30-Calculation of Earnings per Equity Share [EPS]:</b>			
The numerators and denominators used to calculate the basic and diluted EPS are as follows:			
A Loss attributable to Shareholders	INR-Lakh	(1,149)	(2,124)
B Basic and weighted average number of Equity shares outstanding during the year	Numbers	1,00,00,000	1,00,00,000
C Effect of dilution - 8% Optionally Convertible Non-cumulative Redeemable Preference Shares	Numbers	7,06,82,192	4,28,49,727
D Weighted average number of Equity shares adjusted for the effect of dilution	Numbers	8,06,82,192	5,28,49,727
E Nominal value of equity share	INR	10	10
F Basic EPS	INR	(11.49)	(21.24)
G Diluted EPS	INR	(1.42)	(4.02)
<b>Note: 31-Segment Information:</b>			
The Chief Operating Decision Maker [CODM] reviews the Company as a single segment, namely " Pharmaceuticals Business".			
Revenue derived from a single customers which amount to 10% or more of total sales		14,004	6,943
<b>Note: 32-Related Party Transactions:</b>			
<b>A Name of the Related Parties and Nature of the Related Party Relationship:</b>			
<b>a Holding Company:</b>	Zydus Lifesciences Limited		
<b>b Fellow Subsidiaries/ Concerns:</b>	<p>Nesher Pharmaceuticals (USA) LLC [USA] [Merged with ZPUI w.e.f. October 25, 2024]</p> <p>ZyVet Animal Health Inc. [USA]</p> <p>Zydus Healthcare (USA) LLC [USA]</p> <p>Sentynl Therapeutics Inc. [USA]</p> <p>Zydus Noveltech Inc. [USA] [dissolved on December 15, 2023]</p> <p>Hercon Pharmaceuticals LLC [USA] [dissolved on May 24, 2023]</p> <p>Viona Pharmaceuticals Inc. [USA]</p> <p>Zydus Therapeutics Inc. [USA]</p> <p>Zynext Ventures USA LLC [USA]</p> <p>Zydus Healthcare S.A. (Pty) Ltd [South Africa]</p> <p>Alidac Pharmaceuticals SA Pty. Ltd.</p> <p>Script Management Services (Pty) Ltd [South Africa]</p> <p>Zydus Wellness [BD] Pvt Ltd [Bangladesh]</p> <p>Zydus Pharmaceuticals Mexico SA De C.V. [Mexico]</p> <p>Zydus Pharmaceuticals Mexico Services Company SA De C.V.[Mexico]</p> <p>Zydus Worldwide DMCC [UAE]</p> <p>Zydus Wellness International DMCC [UAE]</p>		
Zydus Healthcare Limited			
German Remedies Pharmaceuticals Private Limited			
Zydus Wellness Limited			
Zydus Wellness Products Limited			
Liva Nutritions Limited			
Liva Investment Limited [under liquidation]			
Zydus Animal Health and Investments Limited [ZAHIL]			
Dialforhealth Unity Limited			
Dialforhealth Greencross Limited			
Violio Healthcare Limited			
Biochem Pharmaceutical Private Limited			
Zydus Strategic Investments Limited			
Zydus VTEC Limited			
LM Manufacturing India Private Limited [w.e.f. November 6, 2023]			
M/s. Recon Pharmaceuticals and Investments, a Partnership Firm			
Zydus Medtech Private Limited [w.e.f. May 31, 2024]			
Naturell (India) Private Limited [w.e.f. December 2, 2024]			
Zydus International Private Limited [Ireland]			

**ZYDUS PHARMACEUTICALS LIMITED**

**Notes to the Financial Statements**

**Note: 32-Related Party Transactions-Continued:**

ZyduS Netherlands B.V. [the Netherlands]	ZyduS Lifesciences Global FZE [UAE] [w.e.f. February 20, 2024]
ZyduS Lanka (Private) Limited [Sri Lanka]	ZyduS Pharmaceuticals (Canada) Inc. [Canada] [w.e.f. September 6, 2023]
ZyduS Nikkho Farmaceutica Ltda. [Brazil]	ZyduS Pharmaceuticals UK Limited [UK]
Alidac Healthcare (Myanmar) Limited [Myanmar]	LM Manufacturing Limited [UK][w.e.f. November 6, 2023]
ZyduS Healthcare Philippines Inc. [Philippines]	Medsolutions (Europe) Limited [UK] [w.e.f. November 6, 2023]
Zynext Ventures PTE. LTD. [Singapore]	LiqMeds Worldwide Limited [UK] [w.e.f. November 6, 2023]
ZyduS France, SAS [France]	LiqMeds Limited [UK] [w.e.f. November 6, 2023]
Laboratorios Combix S.L. [Spain]	LiqMeds Lifecare Limited [UK] [LiqMed] [w.e.f. November 6, 2023]
Etna Biotech S.R.L. [Italy]	Naturell Inc. [USA] [w.e.f. December 2, 2024]
ZyduS Pharmaceuticals (USA) Inc. [ZPUI] [USA]	

**c Joint Venture [JV] Companies:**

ZyduS Hospira Oncology Private Limited [JV of ZLL]	Bayer ZyduS Pharma Private Limited [Up to May 2, 2024] [JV of ZLL]
ZyduS Takeda Healthcare Private Limited [JV of ZLL]	Oncosol Limited [w.e.f. November 6, 2023] [JV of LiqMed]
Sterling Biotech Limited [w.e.f. August 29, 2024] [JV of ZAHIL]	

**d Enterprises significantly influenced by Holding Company with whom transactions have taken place:**

ZyduS Infrastructure Private Limited	ZyduS Hospitals and Healthcare Research Private Limited
Mukesh M. Patel & Co.	

**e Key Managerial Personnel:**

Mr. Prashant Sharma	Director	Mr. Vishal Shah	Wholetime Director
Mr. Chimanlal Patel	Director	Mr. Jignesh Thosani	Chief Financial Officer
Mr. Mukund Thakkar	Director	Mr. Dhaval Soni	Company Secretary
Mrs. Sujatha Rajesh	Women Director (w.e.f. May 10, 2024)		

**f Post Employment Benefits Plans with whom transactions have taken place:**

ZyduS Pharmaceuticals Limited Employees Group Gratuity Scheme

**B Transactions with Related Parties:**

The following transactions were carried out with the related parties in the ordinary course of business and at arm's length terms:

**a** Details relating to parties referred to in Note 32A [a, b & d]

Nature of Transactions	INR-Lakh					
	Holding Company		Fellow Subsidiary Companies		Enterprises significantly influenced by Holding Company	
	Year ended March 31		Year ended March 31		Year ended March 31	
	2025	2024	2025	2024	2025	2024
<b>Purchases:</b>						
<b>Goods:</b>						
ZyduS Lifesciences Limited	3,662	3,858	-	-	-	-
<b>Services:</b>						
ZyduS Lifesciences Limited	21	21	-	-	-	-
ZyduS Infrastructure Private Limited	-	-	-	-	355	387
Others	-	-	-	-	2	-
<b>Property, Plant and Equipment</b>						
ZyduS Lifesciences Limited	8	59	-	-	-	-
<b>Sales:</b>						
<b>Goods:</b>						
ZyduS Lifesciences Limited	655	1	-	-	-	-
<b>Services:</b>						
ZyduS Lifesciences Limited	13,486	5,171	-	-	-	-
ZyduS Worldwide DMCC	-	-	(68)	1,791	-	-
ZyduS Lifesciences Global FZE	-	-	703	-	-	-
<b>Finance:</b>						
<b>Issue of Preference shares</b>						
ZyduS Lifesciences Limited	10,000	66,000	-	-	-	-
<b>Inter Corporate Loan accepted</b>						
ZyduS Healthcare Limited	-	-	-	7,285	-	-
<b>Inter Corporate Loan repaid to:</b>						
ZyduS Healthcare Limited	-	-	-	56,000	-	-
<b>Interest expenses:</b>						
ZyduS Healthcare Limited	-	-	-	1,224	-	-
			As at March 31			
	2025	2024	2025	2024	2025	2024
<b>Outstanding:</b>						
<b>Payable:</b>						
ZyduS Lifesciences Limited	3,000	3,962	-	-	-	-
ZyduS Healthcare Limited	-	-	-	-	-	-
ZyduS Infrastructure Private Limited	-	-	-	-	47	28
<b>Receivable:</b>						
ZyduS Lifesciences Limited	4,384	1,960	-	-	-	-
ZyduS Worldwide DMCC	-	-	-	68	-	-
ZyduS Lifesciences Global FZE	-	-	150	-	-	-

**ZYDUS PHARMACEUTICALS LIMITED**

**Notes to the Financial Statements**

**Note: 32-Related Party Transactions-Continued:**

INR-Lakh

Year ended March 31

**2025**                      **2024**

<b>b</b> Details relating to persons referred to in Note-32A [e] above:		
[i] Salaries and other employee benefits to executive officers of the company	<b>135</b>	119
[ii] Outstanding payable to above [i]	<b>5</b>	4
<b>c</b> Details relating to persons referred to in Note-32A[f] above:		
[i] Contributions [including Employees' share and contribution]	<b>73</b>	97
<b>d</b> There are no transactions with parties referred to in items 32A[c].		

**Note: 33-Financial Instruments:**

**A Fair values hierarchy:**

Financial assets and financial liabilities measured at fair value in the statement of financial position are grouped into three Levels of a fair value hierarchy. The three Levels are defined based on the observability of significant inputs to the measurement, as follows:

Level 1: Quoted prices [unadjusted] in active markets for financial instruments.

Level 2: Inputs other than quoted prices included within Level 1 which are observable for the assets or liabilities, either directly or indirectly.

Level 3: If one or more of the significant inputs is not based on observable market data, the instrument is included in level 3.

**B Financial assets and liabilities measured at fair value - recurring fair value measurements:**

	INR-Lakh			
	As at March 31, 2025			
	Level 1	Level 2	Level 3	Total
<b>Financial assets:</b>				
<b>Financial assets at FVTPL:</b>				
Mutual funds	2,877	-	-	<b>2,877</b>
	<b>2,877</b>	-	-	<b>2,877</b>
<b>Financial liabilities</b>				
	-	-	-	<b>-</b>
	As at March 31, 2024			
	Level 1	Level 2	Level 3	Total
<b>Financial assets:</b>				
<b>Financial assets at FVTPL:</b>				
Mutual funds	1,831	-	-	<b>1,831</b>
	<b>1,831</b>	-	-	<b>1,831</b>
<b>Financial liabilities</b>				
	-	-	-	<b>-</b>

**C Fair value of instruments measured at amortised cost:**

**Financial Assets:**

The carrying amounts of trade receivables, other financial assets and cash and cash equivalents are considered to be the approximately equal to the fair values.

**Financial Liabilities:**

Fair values of trade payables and other financial liabilities are considered to be approximately equal to the carrying values.

**Note: 34-Financial Risk Management:**

**A Financial instruments by category:**

	INR-Lakh			
	As at March 31, 2025			
	FVTPL	FVOCI	Amortised Cost	Total
<b>Financial assets:</b>				
Non Current Other Financial Assets			1	<b>1</b>
Investments - Mutual Funds	2,877	-	-	<b>2,877</b>
Trade receivables	-	-	4,510	<b>4,510</b>
<b>Total</b>	<b>2,877</b>	-	<b>4,511</b>	<b>7,388</b>
<b>Financial liabilities:</b>				
Trade payables	-	-	4,925	<b>4,925</b>
Non Current Other Financial Liabilities	-	-	25	<b>25</b>
Payable for Capital Goods	-	-	879	<b>879</b>
Book Overdraft	-	-	13	<b>13</b>
Other Current Financial Liabilities	-	-	373	<b>373</b>
<b>Total</b>	<b>-</b>	<b>-</b>	<b>6,215</b>	<b>6,215</b>

**ZYDUS PHARMACEUTICALS LIMITED**  
**Notes to the Financial Statements**

**Note: 34-Financial Risk Management-Continued:**

	INR-Lakh			
	As at March 31, 2024			
	FVTPL	FVOCI	Amortised Cost	Total
<b>Financial assets:</b>				
Non Current Other Financial Assets	-	-	1	1
Investments - Mutual Funds	1,831	-	-	1,831
Cash and Cash Equivalents	-	-	63	63
Trade receivables	-	-	2,027	2,027
<b>Total</b>	<b>1,831</b>	<b>-</b>	<b>2,091</b>	<b>3,922</b>
<b>Financial liabilities:</b>				
Trade payables	-	-	4,999	4,999
Non Current Other Financial Liabilities	-	-	7	7
Payable for Capital Goods	-	-	2,069	2,069
Other Current Financial Liabilities	-	-	287	287
<b>Total</b>	<b>-</b>	<b>-</b>	<b>7,362</b>	<b>7,362</b>

**B Risk Management:**

The Company's activities expose it to market risk, liquidity risk and credit risk. This note explains the sources of risk which the entity is exposed to and how the entity manages the risk and the related impact in the financial statements.

The Company's risk management is done in close co-ordination with the board of directors and focuses on actively securing the Company's short, medium and long-term cash flows by minimizing the exposure to volatile financial markets. Long-term financial investments are managed to generate lasting returns. The Company does not actively engage in the trading of financial assets for speculative purposes nor does it write options.

The most significant financial risks to which the Company is exposed are described below:

**a Credit risk:**

Credit risk arises from the possibility that counter party may not be able to settle its obligations as agreed. The Company is exposed to credit risk from loans and other financial assets. The Company periodically assesses the financial reliability of the counter party taking into account the historical cost.

- Bank deposits : The Company maintains its Cash and cash equivalents and Bank deposits with reputed and highly rated banks. Hence, there is no significant credit risk on such deposits.
- Trade Receivable: The Company trades with recognized and credit worthy third parties. It is the Company's policy that all customers who wish to trade on credit terms are subject to credit verification procedures. In addition, receivable balances are monitored on an on-going basis with the result that the Company's exposure to credit losses is not significant.
- There are no significant credit risks with related parties of the Company. The Company is exposed to credit risk in the event of non-payment by customers. Credit risk concentration with respect to trade receivables is mitigated by the Company's large customer base.

Adequate expected credit losses are recognized as per the assessments. No single third party customer contributes to more than 10% of outstanding accounts receivable [excluding outstanding from subsidiaries] as at March 31, 2025 and March 31, 2024.

The Company has used lifetime expected credit loss [ECL] model for assessing the impairment loss. For the purpose, the Company uses a provision matrix to compute the expected credit loss amount. The provision matrix takes into account external and internal risk factors and historical data of credit losses from various customers. Financial assets for which loss allowances is measured using the expected credit loss:

	INR-Lakh	
	As at March 31	
	2025	2024
<b>Trade Receivables:</b>		
Less than 180 days [including not due]	4,510	2,027
180 - 365 days	-	-
Above 365 days	-	-
<b>Total</b>	<b>4,510</b>	<b>2,027</b>

Other than trade receivables, the Company has no significant class of financial assets that is past due but not impaired.

**b Liquidity risk:**

- Prudent liquidity risk management implies maintaining sufficient cash and marketable securities and the availability of funding through an adequate amount of committed credit facilities to meet obligations when due. Due to the nature of the business, the Company maintains flexibility in funding by maintaining availability under committed facilities.
- Management monitors rolling forecasts of the Company's liquidity position and cash and cash equivalents on the basis of expected cash flows. The Company takes into account the liquidity of the market in which it operates. In addition, the Company's liquidity management policy involves projecting cash flows in major currencies and considering the level of liquid assets necessary to meet these, monitoring balance sheet liquidity ratios against internal and external regulatory requirements and maintaining debt financing plans. The holding company has also ensured the company about the funding requirements that may arise from time to time so as to have smooth functioning of the company.

**Maturities of financial liabilities:**

The tables below analyse the Company's financial liabilities into relevant maturity groupings based on their contractual maturities for all non-derivative financial liabilities. The amounts disclosed in the table are the contractual undiscounted cash flows. Balances due within 12 months equal their carrying balances as the impact of discounting is not significant.

**ZYDUS PHARMACEUTICALS LIMITED**

**Notes to the Financial Statements**

**Note: 34-Financial Risk Management-Continued:**

		INR-Lakh				
		< 1 year	1-2 year	2-3 year	> 3 years	Total
		As at March 31, 2025				
<b>Non-derivative Financial Liabilities:</b>						
Trade payables	4,925	-	-	-	-	4,925
Non Current Other Financial Liabilities	-	-	-	-	25	25
Payable for Capital Goods	879	-	-	-	-	879
Book Overdraft	13	-	-	-	-	13
Other Current Financial Liabilities	373	-	-	-	-	373
<b>Total</b>	<b>6,190</b>	<b>-</b>	<b>-</b>	<b>25</b>	<b>25</b>	<b>6,215</b>
		INR-Lakh				
		< 1 year	1-2 year	2-3 year	> 3 years	Total
		As at March 31, 2024				
<b>Non-derivative Financial Liabilities:</b>						
Trade payable	4,999	-	-	-	-	4,999
Non Current Other Financial Liabilities	-	-	-	-	7	7
Payable for Capital Goods	2,069	-	-	-	-	2,069
Other Current Financial Liabilities	287	-	-	-	-	287
<b>Total</b>	<b>7,355</b>	<b>-</b>	<b>-</b>	<b>7</b>	<b>7</b>	<b>7,362</b>

**c Foreign currency risk:**

The Company is exposed to foreign exchange risk arising from foreign currency transactions, primarily with respect to the US Dollar. Foreign exchange risk arises from recognised assets and liabilities denominated in a currency that is not the Company's functional currency. The Company's operations in foreign currency creates natural foreign currency hedge. This results in insignificant net open foreign currency exposures considering the volumes operations of the Company.

**Foreign currency risk exposure:**

The Company's exposure to foreign currency risk at the end of the reporting period expressed in INR-Lakh, are as follows:

		INR-Lakh	
		Exposure of USD	
		As at March 31	
		2025	2024
<b>Financial assets:</b>			
Trade and other receivable		1,585	2,152
<b>Total exposure to foreign currency risk [assets]</b>		<b>1,585</b>	<b>2,152</b>
<b>Financial liabilities:</b>			
Trade and other payable		3,402	3,968
<b>Total exposure to foreign currency risk [liabilities]</b>		<b>3,402</b>	<b>3,968</b>
<b>Net exposure to foreign currency risk</b>		<b>(1,817)</b>	<b>(1,816)</b>

		INR-Lakh	
		Exposure of Other Foreign Currencies	
		As at March 31	
		2025	2024
<b>Financial assets:</b>			
Trade and other receivable		349	144
<b>Total exposure to foreign currency risk [assets]</b>		<b>349</b>	<b>144</b>
<b>Financial liabilities:</b>			
Trade and other payable		8	42
<b>Total exposure to foreign currency risk [liabilities]</b>		<b>8</b>	<b>42</b>
<b>Net exposure to foreign currency risk</b>		<b>341</b>	<b>102</b>

**Sensitivity \*:**

The sensitivity of profit or loss and equity to changes in the exchange rates arises mainly from foreign currency denominated financial instruments:

		INR-Lakh				
		As at March 31, 2025			As at March 31, 2024	
	Movement in Rate	Impact on PAT [*]	Impact on OCI [*]	Movement in Rate	Impact on PAT [*]	Impact on OCI [*]
USD	2.50%	(38)	-	1.50%	(23)	-
USD	-2.50%	38	-	-1.50%	23	-
Others	4.00%	11	-	1.00%	3	-
Others	-4.00%	(11)	-	-1.00%	(3)	-

\* Holding all other variables constant

**d Interest rate risk:**

The Company's policy is to minimize interest rate cash flow risk exposures on long-term financing. As at March 31, 2025, the Company is not exposed to changes in market interest rates through borrowings at variable interest rates. The Company's investments in Fixed Deposits are at fixed interest rates.

**ZYDUS PHARMACEUTICALS LIMITED**  
**Notes to the Financial Statements**

**Note: 34-Financial Risk Management-Continued:**

**e Price risk:**

**Exposure:**

The Company's exposure to price risk arises from investments in equity and mutual funds held by the Company and classified in the balance sheet as fair value through OCI and at fair value through profit or loss respectively. To manage its price risk arising from investments in equity securities and mutual funds, the Company diversifies its portfolio.

Diversification of the portfolio is done in accordance with the limits set by the Company.

**Sensitivity \*:**

The table below summarises the impact of increases/decreases of the index on the Company's equity and profit or loss for the period.

	Movement in Rate	INR-Lakh			
		As at March 31, 2025		As at March 31, 2024	
		Impact on PAT	Impact on OCI	Impact on PAT	Impact on OCI
<b>Mutual Funds [Quoted]</b>					
Increase	+2.00%	58	-	37	-
Decrease	-2.00%	(58)	-	(37)	-

\* Holding all other variables constant

**Note: 35-Capital Management:**

The Company's capital management objectives are:

- To ensure the Company's ability to continue as a going concern
- To provide an adequate return to shareholders
- To maintain an optimal capital structure to reduce the cost of capital.

Management assesses the Company's capital requirements in order to maintain an efficient overall financing structure while avoiding excessive leverage.

This takes into account the subordination levels of the Company's various classes of debt. The Company manages the capital structure and makes adjustments to it in the light of changes in economic conditions and the risk characteristics of the underlying assets.

**Note: 36-Leases:**

**Lessee:**

**A Relating to statement of financial position:**

- Under Ind AS 116, the Company recognises right to use assets and lease liabilities for most leases. Right of use assets are part of financial statement caption "Property plant and equipment". Depreciation and impairment is similar to measurement of owned assets.

Right of use assets	INR-Lakh	
	Land	Total
<b>Balance as at March 31, 2023 [Net]</b>	4,320	4,320
Additions during the year	-	-
Depreciation charge for the year	45	45
<b>Balance as at March 31, 2024 [Net]</b>	<b>4,275</b>	<b>4,275</b>
Additions during the year	-	-
Depreciation charge for the year	45	45
<b>Balance as at March 31, 2025 [Net]</b>	<b>4,230</b>	<b>4,230</b>

**Note: 37-Analytical Ratios:**

#	Ratio	Numerator	Denominator	FY 24-25	FY 23-24	% Change
1	Current Ratio[i]	Current Assets	Current Liabilities	2.29	1.13	103%
2	Debt-Equity Ratio	Total Debt	Shareholder's Equity	N.A.	N.A.	N.A.
3	Debt Service Coverage Ratio[ii]	Earnings available for debt service @	Finance cost + Repayment of debt	N.A.	(0.02)	100%
4	Return on Equity Ratio[iii]	Net Profits after taxes	Average Shareholder's Equity	(1.69%)	(6.67%)	75%
5	Inventory Turnover Ratio	Net Sales	Average Inventory	2.61	2.42	8%
6	Trade Receivables Turnover Ratio	Net Sales	Average Trade Receivables	4.48	5.65	(21%)
7	Trade payables turnover ratio [iv]	Net Purchases and Other	Average Trade Payables	0.93	1.56	(40%)
8	Net Capital Turnover Ratio[v]	Net Sales	Average Working Capital	3.18	(1.90)	267%
9	Net Profit Ratio[vi]	Net Profits after taxes	Net Sales	(7.85%)	(30.59%)	74%
10	Return on Capital employed [vii]	Earnings before interest and taxes	Average Capital Employed	(1.95%)	(3.63%)	46%
11	Return on investments:					
a	Fixed Deposits	Income from investments during the year	Time weighted average of investments	7.00%	7.00%	NA
b	Mutual Funds	Income from investments during the year	Time weighted average of investments	7.00%	6.91%	1.3%

[i] Mainly due to increase in inventories, trade receivables & investment and decrease in payable for capital goods.

[ii] Mainly due to decrease in loss and no outstanding borrowing during the current year as the company has fully repaid borrowing in last year.

[iii] Mainly due to decrease in loss and increase in average equity.

[iv] Due to increase in purchase & average trade payable.

[v] Mainly due to increase in Contract Manufacturing Income and average working capital.

[vi] Mainly due to increase in Contract Manufacturing Income and decrease in loss.

[vii] Mainly due to decrease in loss and increase in average capital employed.

[@] Net profit after taxes + non cash operating expenses + finance cost - other income.

**ZYDUS PHARMACEUTICALS LIMITED****Notes to the Financial Statements****Note: 38:**

- a The Company has not advanced or loaned or invested funds [either from borrowed funds or share premium or any other sources or kind of funds ] to any other persons or entities, including foreign entities [Intermediaries], with the understanding, whether recorded in writing or otherwise that the Intermediary shall directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company [Ultimate Beneficiaries] or provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries.
- b The Company has not received any funds from any persons or entities, including foreign entities [Funding Party] with the understanding [whether recorded in writing or otherwise], that the Company shall, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party [Ultimate Beneficiaries] or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.
- c The Company has used accounting software for maintaining its books of accounts for the year ended on March 31, 2025 which has a feature of recording audit trail [edit log] facility and the same has been operational throughout the year for all relevant transactions recorded in the software. Audit trail has been preserved by the Company as per the statutory requirements for record retention.
- d The Company has not traded or invested in Crypto currency or Virtual currency during the financial year.
- e No proceedings have been initiated or pending against the Company for holding any benami property under the Benami Transactions [Prohibition] Act, 1988 (45 of 1988) and the rules made thereunder.
- f The Company has not been declared as wilful defaulter by any bank or financial Institution or other lender.
- g The Company does not have any charges or satisfaction yet to be registered with Registrar of Companies beyond the statutory period.
- h The Company has complied with the number of layers prescribed under clause [87] of section 2 of the Act read with Companies [Restriction on number of Layers] Rules, 2017.
- i No Scheme of Arrangements has been approved by the Competent Authority in terms of sections 230 to 237 of the Companies Act, 2013.
- j The Company does not have any transaction which is not recorded in the books of accounts that has been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 [such as, search or survey or any other relevant provisions of the Income Tax Act, 1961].

**Note: 39-Disclosure of transactions with Struck off Companies:**

The Company did not have any material transaction with companies struck off under Section 248 of the Companies Act, 2013 or Section 560 of Companies Act, 1956 during the current and previous financial year.

**Note: 40:**

Figures of previous reporting year have been regrouped/ reclassified to conform to current year's classification.

**Signatures to Material Accounting Policies and Notes 3 to 40 to the Financial Statements**

As per our report of even date

For Mukesh M. Shah & Co.

Chartered Accountants

Firm Registration Number:106625W

For and on behalf of the Board

sd/-

Prashant Sharma

Chairman

[DIN - 06812786]

sd/-

Vishal Shah

Whole-time Director

[DIN - 08005523]

sd/-

Karnik K Shah

Partner

Membership Number:129675

Ahmedabad, Dated : May 12, 2025

sd/-

Jignesh Thosani

Chief Financial Officer

sd/-

Dhaval Soni

Company Secretary

Ahmedabad, Dated : May 12, 2025